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ABSTRACT 
The accuracy of prognostic and therapy-predictive biomarker assessment in breast tumours is 
crucial for management and therapy decision in patients with breast cancer. In this thesis, 
biomarkers used in clinical practice with emphasise on Ki67 and HER2 were studied using 
several methods including immunocytochemistry, immunohistochemistry, in situ 
hybridisation, gene expression assays and digital image analysis, with the overall aim to 
improve routine biomarker evaluation and clarify the prognostic potential in early breast 
cancer. 
In paper I, we reported discordances in biomarker status from aspiration cytology and paired 
surgical specimens from breast tumours. The limited prognostic potential of 
immunocytochemistry-based Ki67 scoring demonstrated that immunohistochemistry on 
resected specimens is the superior method for Ki67 evaluation. In addition, neither of the 
methods were sufficient to predict molecular subtype. Following this in paper II, biomarker 
agreement between core needle biopsies and subsequent specimens was investigated, both in 
the adjuvant and neoadjuvant setting. Discordances in Ki67 and HER2 status between core 
biopsies and paired specimens suggested that these biomarkers should be re-tested on all 
surgical breast cancer specimens. In paper III, digital image analysis using a virtual double 
staining software was used to compare methods for assessment of proliferative activity, 
including mitotic counts, Ki67 and the alternative marker PHH3, in different tumour regions 
(hot spot, invasive edge and whole section). Digital image analysis using virtual double staining 
of hot spot Ki67 outperformed the alternative markers of proliferation, especially in 
discriminating luminal B from luminal A tumours. Replacing mitosis in histological grade with 
hot spot-scored Ki67 added significant prognostic information. Following these findings, the 
optimal definition of a hot spot for Ki67 scoring using virtual double staining in relation to 
molecular subtype and outcome was investigated in paper IV. With the growing evidence of 
global scoring as a superior method to improve reproducibility of Ki67 scoring, a different 
digital image analysis software (QuPath) was also used for comparison. Altogether, we found 
that automated global scoring of Ki67 using QuPath had independent prognostic potential 
compared to even the best virtual double staining hot spot algorithm, and is also a practical 
method for routine Ki67 scoring in breast pathology. In paper V, the clinical value of HER2 
status was investigated in a unique trastuzumab-treated HER2-positive cohort, on the protein, 
mRNA and DNA levels. The results demonstrated that low levels of ERBB2 mRNA but neither 
HER2 copy numbers, HER2 ratio nor ER status, was associated with risk of recurrence among 
anti-HER2 treated breast cancer patients. 
In conclusion, we have identified important clinical aspects of Ki67 and HER2 evaluation and 
provided methods to improve the prognostic potential of Ki67 using digital image analysis. In 
addition to protein expression of routine biomarkers, mRNA levels by targeted gene expression 
assays may add further prognostic value in early breast cancer.  
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1 INTRODUCTION 
1.1 DEVELOPMENT AND ANATOMY OF THE MAMMARY GLAND 
1.1.1 The development of the mammary gland 
The mammary glands, or breasts, are one of the characteristic features of mammals and are 
found in both sexes. During the embryologic development several glands develop along the 
mammary ridges, which are bilateral ectodermal thickenings, formed along the developing 
axilla extending to the inguinal region. In contrast to other mammals, only one pair of cell 
groups develop further in humans and form the rudimentary breast tissue on each side. At birth 
the mammary glands are rudimentary in both sexes but are to some extent responsive to 
maternal hormones. The ducts of the mammary tissue continue to elongate and branch. In 
females, this development is accelerated during puberty under the influence of hormones:  
Ovarian oestrogen and progesterone promotes the proliferation, differentiation and remodelling 
of the ducts and connective tissue to form the adult mammary glands. 
The adult mammary glands are influenced by hormone levels during the menstrual cycle. 
Proliferation of the ductal epithelium occurs during the second half of the menstrual cycle, and 
sequential apoptosis follows with decreased levels of estrogen and progesterone at onset of 
menstruation. During pregnancy, the number of terminal ducts increases significantly and at 
this stage the mammary tissue mainly consists of lobular epithelium. During lactation, the 
terminal duct lobular units (TDLU) are enlarged, the epithelium becomes vacuolised, and the 
lumina of the ducts are distended by secretory material. The initiation of milk secretion is 
induced by prolactin and the ejection of milk is stimulated by oxytocin release from the 
adenohypophysis and neurohypophysis, respectively. Influenced by the altered hormonal 
environment at menopause, the TDLUs atrophy, but the intermediate and larger duct systems 
remain. Cystic dilation of residual ducts is frequently observed along with a decrease in 
interlobular fibrous connective tissue leading to an increase in the percentage of adipose tissue 
content.  
1.1.2 The anatomy of the mammary gland 
The breast is predominantly composed of adipose and glandular tissue along with connective 
tissue. It is covered by skin, rests on the pectoralis muscle and is posteriorly separated by a 
fascia. The mammary gland contains around 15-20 lobes with each lobe comprising of 20-40 
TDLUs1, 2. The TDLU is the most important functional unit of the breast and consist of 
extralobular- and intralobular terminal ducts and acini (Figure 1). The ducts are composed of a 
double layer of epithelium: the innermost luminal epithelial cell layer, which is lined by a 
myoepithelial cell layer resting on a basal membrane1. The ductal system is surrounded by the 
stromal compartment, which comprises endothelial cells, fibroblasts, macrophages and 
inflammatory cells. The TDLUs are closely surrounded by a specialised, myxoid-like 
hormone-sensitive connective tissue with absence of elastic fibres. The foremost described 
development of the mammary gland is dependent on the interaction between the specialised 
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epithelium and its stroma. Surrounding larger ducts, continuous and well-developed elastic 
tissue is present with a smaller content of specialised stroma. The TDLUs are connected with 
larger ducts through subsegmental and segmental ducts that in turn lead to collecting ducts, 
which empty into the nipple3. Pathological changes in the TDLUs are believed to give rise to 
the majority of breast carcinomas and ductal carcinoma in situ (DCIS). The precursor lesions 
to invasive breast cancer are DCIS, which is a premalignant epithelial proliferation within the 
ducts, and lobular neoplasia confined to the lobules4.  
The mammary gland is well vascularised and supplied by the thoracic branches of the axillary 
artery, the internal thoracic artery and the anterior intercostal arteries2. The breast is supplied 
by sensory innervation from the second to sixth intercostal nerves and the supraclavicular 
nerve. The lymphatic system of the breast mainly drains to lower pectoralis axillary lymph 
nodes and further up to the supraclavicular nodes (75%)2. The axillary lymph nodes are divided 
into six group based on their relation to the pectoralis minor muscle, and recognised by 
surgeons. Lymphatic drainage also occurs to the parasternal lymph nodes, especially from the 
medial part of the breast. Furthermore, superficial lymphatic drainage may occur to the 
contralateral breast or the abdominal wall. In the case of direct metastasis to the supraclavicular 
lymph nodes, this indicates an advanced stage of disease. Lymphatic drainage of the breast 
tissue is the main route for breast cancer cells to metastasise. 
 
Figure 1. The anatomy of the mammary gland and the terminal duct lobular unit (TDLU).  
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1.2 BREAST CANCER - GENERAL BACKGROUND 
The first description of cancer dates back to Egypt around 3000 BC and breast cancer is 
described in an ancient Egyptian textbook and furthermore mentioned by Hippocrates around 
460 BC5. The modern era of surgical treatment for breast cancer dates back to 1894, when 
Halsted and Meyer introduced the radical mastectomy6, 7. This surgical removal of the tumour 
involved all breast tissue, the pectoralis muscles, all axillary lymph nodes and overlying skin, 
and led to postoperative complications. The current knowledge has led to the understanding 
that breast cancer is a heterogeneous disease consisting of several diverse entities with complex 
patterns of genetic and epigenetic alterations, presenting different morphological features, 
clinical behaviour, and response to treatment. 
1.2.1 Epidemiology of breast cancer 
Breast cancer is the most common malignant disease in women worldwide, with over 2 million 
new cases and 627,000 deaths in 20188, 9. In the United States, more than 275,000 new cases 
and 42,000 deaths are expected in 202010. In 2018, the United States had an age-standardised 
incidence rate of 84.8 per 100,0009. A similar incidence rate of 83.2 per 100,000 was seen in 
Sweden11. In 2016, the incidence of breast cancer in Sweden was 7,240 new cases11. Since the 
beginning of the 1960’s, the incidence rate has almost doubled and at the same time there has 
been a steady decrease in the mortality rate in Sweden. The relative ten-year survival rate for 
breast cancer has increased from 50% to around 80% since the beginning of the 1960’s, and 
the relative five-year survival reached 83% in 201912, 13. The decrease in mortality is most likely 
a result of advances in treatment and earlier detection through screening programs14, 15.   
1.2.2 Risk factors and hereditary breast cancer 
The aetiology of breast cancer is multifactorial and involves reproductive factors such as 
hormones and several epidemiologic factors. The most well-established risk factors for breast 
cancer are nulliparity, high age at first delivery, lack of breastfeeding, early menarche, late 
menopause, hormone replacement therapy, and mammographic density8. The association of 
several risk factors with breast cancer, e. g. parity and breastfeeding, are shown to vary across 
different molecular subtypes16-18.  
Hereditary breast cancer with known high-penetrance gene mutations is seen in 5-10% of all 
breast cancers. The most common mutations are found in the DNA repair genes BRCA1 and 
BRCA2, which leads to a 70% lifetime risk of developing breast cancer. The prognosis of breast 
cancer is highly variable and dependent on several prognostic variables, which will be 
described below. 
1.3 CARCINOGENESIS AND PATHOGENESIS OF BREAST CANCER 
1.3.1 The hallmarks of cancer 
Human tumour pathogenesis has been extensively described by Hanahan and Weinberg with 
the ten established hallmarks of cancer (Figure 2)19, 20. The core hallmarks for comprehensively 
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describing the neoplastic process include sustaining proliferative signalling, evading growth 
suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis and 
activating invasion and metastasis19.  
Figure 2. The hallmarks of cancer. Modified from Hanahan and Weinberg 201119, reproduced with 
permissions from Elsevier. 
One of the foremost features of cancer cells is the capability to sustain chronic proliferation. 
Cancer cells overcome growth regulation by e.g. becoming self-sufficient in growth factors 
leading to overactive growth factor signalling or interacting with the tumour-associated stroma 
to produce growth factors. Thus, leading to uncontrolled proliferation by activating pathways 
for cell proliferation and inhibiting cell death. In breast cancer, amplification of the human 
epidermal growth factor receptor 2 (HER2) is an excellent example and a candidate for targeted 
therapy, such as the monoclonal antibody trastuzumab (see section 1.6.2). Apart from sustained 
proliferation, cancer cells have the ability to resist cell death e.g. by mutations in apoptosis 
genes, and also acquire the capability of replicative immortality, partly by upregulating 
telomerase. Another hallmark of cancer cells, is their ability to induce angiogenesis by 
releasing vascular endothelial growth factors (VEGF), which also can be targeted by the drug 
bevacizumab21. The complex process of activating invasion and metastasis in a stepwise 
cascade of events and acquired capabilities including an intricate crosstalk between cancer cells 
and the neoplastic stroma. The ‘epithelial-mesenchymal transition’ program is a broad 
regulator of the invasion-metastasis cascade19. Models of tumour progression are further 
described in section 1.3.2.3 and 1.3.2.4. 
Mutations in key genes that control programs for the capabilities above briefly include 
oncogene-activation or loss of function in tumour suppressor genes. Genome instability and 
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mutations, along with tumour-promoting inflammation, are two more recently described 
enabling characteristics. Additionally, the evidence around reprogramming energy metabolism 
and evading immune destruction has emerged as hallmarks19. Avoiding immune destruction is 
one of the hallmarks that has gained huge attention lately. By binding to T cell surface proteins, 
such as programmed cell death protein 1 (PD-1), tumour cells can inhibit the immune response. 
Thereby with antibodies targeting immune cells, such as cytotoxic T-lymphocyte antigen 4 
(CTLA-4) and PD-1 or programmed death ligand 1 (PD-L1) on the tumour cell, the immune 
response can be reactivated. Several antibodies are available for immunotherapy in breast 
cancer (see section 1.6.6 and 1.11.6). 
1.3.2 Pathogenesis of breast cancer 
Armitage and Doll pioneered over 50 years ago by describing the exponential increase in 
cancer rates with age22, 23, and thereby laid the fundaments of a multistage cancer model for 
tumour initiation, promotion and progression24, 25. Breast cancer incidence, however, does not 
follow an exponential curve, and in all of the early multistage cancer models a single age-
specific incidence rate curve were  a key feature26-29. A two-component cancer model was later 
introduced showing two distinct age-specific incidence rate curves; premenopausal early-onset 
oestrogen receptor (ER)-negative tumours and postmenopausal late-onset ER-positive 
tumours30-34. The complexity of this model incorporating gene expression profiling, 
biostatistical models and analytic epidemiology rather show a bimodal age distribution35. 
Based on gene expression profiling it has further been demonstrated that ER-positive and ER-
negative tumours are fundamentally distinct diseases at the transcriptomic level36. The 
pathogenesis of breast cancer is thus described in multiple pathways and models.  
1.3.2.1 The cell of origin of breast cancer 
There are currently two leading models for breast carcinogenesis: the sporadic clonal evolution 
model and the cancer stem cell hypothesis37-39. Studies suggest that these two models may 
complement each other and neither of them provides the entire explanation40. The cancer stem 
cell hypothesis proposes that cancer stem cells, which have the capacity to indefinitely self-
renew and differentiate, drive cancer initiation and progression. Cancer stem cells are 
considered to account for a minority of the tumour cell population and to give rise to metastatic 
disease and recurrence by spread and resistance to therapy40. 
In contrast, the sporadic clonal evolution model states that any normal cell may be the tumour 
initiator once multiple mutations occur providing natural selective growth advantages. This 
Darwinian approach suggests that the most fit and aggressive cells drive cancer progression. 
Over time, subpopulations of different cells develop, leading to tumour heterogeneity40. This 
model demonstrates that therapy resistance is acquired by the selection of cancer cell clones 
that survive therapy-induced microenvironmental pressure41, 42. However, sequencing of 
patient-derived cancer cells with stem cell properties and corresponding differentiated cells 
shows that conversion between the two states is possible43. 
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1.3.2.2 Intratumoural heterogeneity in breast cancer 
A common feature for all cancer types is the vast variety of the cancer cells constituting a single 
tumour44. Simplified, intratumoural heterogeneity is the results of the genetic and phenotypic 
evolution that occurs during tumour progression. Both the cancer stem cell hypothesis and the 
clonal evolution model provide explanations for tumour heterogeneity and are not mutually 
exclusive45. The concept of spatial heterogeneity is the heterogeneity across the subpopulations 
of cells in different regions of the tumour. On the other hand, temporal heterogeneity evolves 
between primary tumour and recurrence46. Tumour heterogeneity is not only observed on a 
genetic and molecular level, but also evident regarding morphological features such as 
histological grade, histological subtype components and phenotypic alterations46, 47.  
Breast cancer is a heterogeneous group of diseases and tumour heterogeneity is a complicating 
factor in clinical practice and cancer treatment, since tumour samples may not represent the 
entire tumour41. Thus, coexistence of several sub clones harbouring different molecular 
aberrations and drug sensitivities may lead to that the therapy is not effective against the whole 
tumour47. Furthermore, tumour heterogeneity is one of the underlying causes of emerging 
therapy resistance47. Most next generation sequencing (NGS) methods analyse the tumour as a 
bulk, but advances in single-cell-sequencing have provided new insights into intratumoural 
heterogeneity. E.g. Rye et al. recently demonstrated on a single-cell level that intratumoural 
heterogeneity for HER2 copy number was associated with worse outcome48. 
1.3.2.3 Models of breast cancer progression 
With the advances in genomic and transcriptomic analyses that have now been performed on 
different stages of breast cancer, the complexity of the biological processes occurring in breast 
cancer progression is even more evident. The molecular subtypes of invasive carcinoma also 
seem to be present in non-invasive DCIS49-51. There are multiple proposed linear models for 
initiation, transformation and progression of breast cancer.  
An historical model assumed that some pre-invasive lesions developed from either the ducts or 
from the lobules, and consequently the terminology of ductal carcinoma in situ and lobular 
carcinoma in situ (LCIS) arose52. Further on, Wellings et al. demonstrated that most of the pre-
invasive lesions develop in the TDLUs53. This step-wise model described how normal 
epithelial cells in the TDLUs transformed into hyperplasia of usual type, then to atypical ductal 
hyperplasia that progressed into low-grade DCIS, and from here either acquire characteristics 
that enabled invasion or progression to high-grade DCIS. A similar lobular model proposed 
that normal cells in the TDLUs transformed into atypical lobular hyperplasia, LCIS and lastly 
invasive lobular carcinoma54, 55. Based on genomic and transcriptomic analyses, the validity of 
this model has been questioned, and it has instead been demonstrated that pre-invasive, in situ 
and invasive lesions of low- and high-grade cluster according to histological grade and not 
stage of tumour progression56, 57. Apart from histological grade as a main influencer on breast 
cancer evolution, molecular studies have proven that the expression of ER and activation of 
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ER-regulated genes form clusters and separate breast tumours into subtypes58-60. Thus, ER-
signalling plays an important role in breast cancer progression. 
The aforementioned models of breast cancer evolution are rather simplified versions of what 
we with the current available knowledge recognise as complex and multiple pathways leading 
to invasive breast cancer. Breast cancer precursor lesions are considered to comprise lesions 
with identical histological, immunohistochemical and molecular attributes with the 
corresponding invasive tumours. These are also referred to as non-obligate precursors, since 
they never have a 100% risk of developing into invasive tumours52. The low-grade precursor 
lesions comprise columnar cell lesions, flat epithelial atypia, atypical lobular neoplasia/classic 
LCIS, atypical ductal hyperplasia and low-grade DCIS. They are all characterised by low 
grade, expression of ER, lack of HER2 overexpression or gene amplification, and harbour 
genetic alterations such as deletions of 16q and gain of 1q61, 62. High grade precursor lesions 
include microglandular adenosis, pleomorphic LCIS and high-grade DCIS, and encompass an 
intricate pattern of genetic alterations52. 
1.3.2.4 From invasive cancer to metastasis 
In breast cancer, death from the disease is a consequence of metastasis to other organs and 
rarely due to the primary tumour in the breast itself. The metastatic process occurs when 
neoplastic cells acquire the ability to not only invade the surrounding microenvironment but to 
pass through the endothelium linings of blood and lymphatic vessel walls. Once in the lymph 
and blood circulation, circulating tumour cells need to be programmed to extravasate at distant 
organ sites and further develop into a secondary tumour63. The seeding of tumour metastases 
is still not completely understood. 
Axillary lymph nodes are the most frequent sites where locoregional metastases from breast 
cancer are found64. The most common organs for distant metastasis are lung, bone, liver, and 
non-axillary lymph nodes65. The metastatic routes from the primary tumor to distant organs 
either by hematogenous or lymphatic seeding, however, are not fully understood. In certain 
subtypes of breast cancer, such as triple-negative breast tumours, distant metastases may occur 
without the involvement of axillary lymph nodes66. At least one study indicates that metastatic 
cells can bypass the axillary lymph nodes and travel directly to distant organs67. Since the 
studies of the thesis only include early primary breast cancer, further details covering the 
metastatic process and tumour heterogeneity in metastases are out of the scope for this thesis. 
1.4 BREAST CANCER DIAGNOSTICS 
The triple diagnostic procedure of a suspicious breast lump includes clinical examination 
(palpation), radiological studies and pathological assessment. 
1.4.1 Radiologic assessment 
Since mammographic screening programs were introduced, breast tumours have been 
diagnosed at an earlier stage. At the same time, an increased number of both invasive and non-
invasive lesions are detected. The screening programme in Sweden invites women of age 40-
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74 with 2-year intervals. Mammographic screening has reduced breast cancer mortality68, 69. In 
Sweden, 65% of all breast tumours are detected through screening programs among eligible 
patients13. Mammography is the preferred modality for radiological evaluation of a suspicious 
breast lump in the majority of patients and has a sensitivity of 85-90%12. The development of 
digital mammography and digital breast tomosynthesis (3D-mammography) has improved the 
diagnostics of diffuse lesions but has not been introduced in general screening. For patients 
with dense breasts, however, and in those with findings on mammography, a complementary 
ultrasound examination is recommended. For women who are under 30 years, pregnant or 
breast feeding, ultrasound examination is the method of choice. In women with uncertain 
lesions, dense breast tissue, increased hereditary risk, or lobular carcinoma, magnetic resonance 
imaging can be used for detailed diagnostics and surgical planning. 
1.4.2 Fine needle aspiration cytology 
Fine needle aspiration cytology (FNAC) is a minimally invasive diagnostic method whereby a 
fine needle (27-22 gauge) is utilised for aspiration of cells from the suspected lesion. The 
aspirated material is immediately smeared on a glass slide (Figure 3) or used for 
immunocytochemistry (ICC). Aspiration cytology can be led by palpation or ultrasound for 
accurately targeting the lesion. FNAC is a rapid method that requires relatively sparse material 
for diagnosis of cancer. In Sweden, the use of FNAC for breast cancer diagnosis has been 
extensively used and developed since the beginning of the 1950’s70, 71. If both clinical 
examination and radiological findings are conclusive for primary surgical removal of the 
tumour, FNAC may be sufficient for diagnosis. The disadvantage of FNAC samples is that the 
tumour material consists of a mixture of aspirated cells without organisation, and thereby, non-
invasive tumours cannot be distinguished from invasive carcinoma. Certain morphological 
information cannot be acquired, such as growth patterns and histological grade. However, some 
anatomical locations may not be available for biopsy sampling other than with a fine needle, 
and in the metastatic setting, FNAC may sometimes be the only choice for diagnosis. 
Figure 3. Fine needle aspiration for aspiration cytology versus a core needle biopsy prepared for 
formalin-fixed paraffin-embedded (FFPE) tissue sections. Created with BioRender.com. 
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1.4.3 Core needle biopsy 
With the core needle biopsy technique, a tissue biopsy is punched out and retracted with a 14-
12 gauge needle. If larger tissue biopsies are required vacuum aspiration (needle of 8 gauge) is 
an alternative method. In the pathology department laboratory, the tissue biopsy is prepared by 
formalin fixation and paraffin embedding after which sections are mounted on glass slides 
(Figure 3). The sections are routinely stained with haematoxylin and eosin (HE) for 
pathological assessment. The advantage of core biopsies is that the tissue and its architecture 
are preserved, which allows for morphological assessment of tumour type and histological 
grade, and for distinguishing in situ from invasive carcinoma. 
Additional immunohistochemistry staining can be performed on biopsy samples, and for all 
breast cancers, a panel of biomarkers (ER, progesterone receptor (PR), HER2, and depending 
on country also Ki67) is routinely assessed. According to international guidelines, biomarker 
evaluation should be performed on either core biopsy or resection specimen, and not solely on 
cytology material12, 72-74. 
With the increasing evidence for the benefits of neoadjuvant therapy, a preoperative biopsy is 
required for diagnosis and biomarker evaluation, which helps to predict the potential benefit of 
neoadjuvant treatment and guide the choice of therapy. For patients with tumours that respond 
well to neoadjuvant therapy, complete response may be reached and no residual tumour cells 
found in the surgical specimen. In this case, the preoperative biopsy with the assessment of 
biomarkers will be the only tumour information provided for deciding on adjuvant therapy. If 
the biomarker evaluations are not accurate, the patient risks either to receive potentially harmful 
therapy without added benefit or miss out on life-saving therapy such as HER2-targeted 
therapy. 
Circulating tumour cells in the blood can be detected in some early cancers and the majority of 
advanced cancers through analysis of so-called liquid biopsies. Two conceptually different 
approaches can be applied; circulating tumor cells or circulating tumor DNA75. Although 
several prospective investigations have been performed, there is not yet evidence for 
implementation in clinical practice76.  
1.4.4 Surgical specimen 
The majority of surgical breast cancer specimens are partial resections from breast-conserving 
surgery or mastectomies (surgical techniques are further presented in section 1.11.1). Surgical 
specimens containing breast tumours are directly sent fresh from surgery to the pathology 
department without prior formalin fixation. The resection margins are inked in order to evaluate 
tumour-free margins by microscopy. The specimen is cut, either in the frontal or sagittal plane 
depending on local traditions, enabling macroscopic assessment of the tumour and its extent. 
This procedure prior to fixation enables biobanking, in which small tumour samples are snap-
frozen and stored in a biobank collection. The stored fresh-frozen tumour material can later be 
used for molecular analysis or for research purposes. Axillary lymph node resections and 
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sentinel node biopsies are included in the surgical samples received for pathological assessment 
(see section 1.11.1).   
1.4.5 Pathological assessment  
Apart from diagnosis and morphological classification including histological grade described 
in detail in section 1.5, the histopathological assessment of specimens from breast tumours and 
axillary content includes evaluation of tumour size, focality, distance to peripheral margins, 
presence of lymphovascular invasion, along with the presence, number and size of lymph node 
metastases. All breast cancer diagnoses are discussed in pre- and postoperative multi-
disciplinary team conferences consisting of a surgical pathologist, radiologist, breast surgeon 
and oncologist as well as team nurses77. 
1.5 MORPHOLOGICAL CLASSIFICATION OF BREAST CANCER 
1.5.1 Non-invasive breast cancer 
DCIS is characterised by intraductal proliferation of malignant epithelium. Large multifocal 
and high-grade DCIS lesions do not generally pose any diagnostic concern. However, small 
low-grade lesion may be difficult to distinguish from atypical ductal hyperplasia and 
consequently lead to a large interobserver variability with both under- and 
overinterpretations78. These lesions are frequently detected by mammographic screening and 
pose a diagnostic challenge78. 
LCIS is the proliferation of neoplastic cells originating from the TDLUs and that expand the 
acini. The loss of E-cadherin or impaired function thereof, caused by CDH1 inactivation, is a 
characteristic feature of lobular lesions79. Impaired E-cadherin leads to loss of cell-cell 
adhesion and augmented proliferation, as well as the architectural alterations morphologically 
recognised as lobular neoplasia80. As mentioned in section 1.3.2.3, LCIS is a non-obligate 
precursor lesion to invasive cancer with a low risk of progression to invasive lobular 
carcinoma81-84, and is not classified as pre-malignant and does not require surgical excision. 
The classification of non-invasive intraductal proliferative breast lesions is continuously 
evolving as new insights and molecular data refine the concept. We can probably expect to see 
changes in the traditional classification along with emerging data on molecular characteristics 
that will support clinical implications.  
1.5.2 Histological subtypes of invasive breast carcinoma 
Invasive breast carcinomas comprise a wide range of morphological phenotypes and are 
categorised into different histological subtypes according to the World Health Organisation 
(WHO)85. The largest group of invasive breast cancers is classified as invasive carcinoma of 
no special type (NST), previously referred to as infiltrating ductal carcinoma or invasive ductal 
carcinoma not otherwise specified. Pure special tumour types that exhibit a special histological 
pattern in ³90% of the tumour, include e.g. lobular, mucinous and tubular carcinoma. Invasive 
lobular carcinoma is the second most common group and together with invasive carcinoma 
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NST, these groups constitute approximately 95% of all breast tumours. Breast tumours 
showing characteristic features are furthermore classified into e.g. cribriform carcinoma, 
apocrine adenocarcinoma, invasive micropapillary carcinoma and metaplastic carcinoma. The 
WHO has classified several other categories of breast tumours with characteristic 
morphology85. Papillary neoplasms, including encapsulated papillary carcinoma, solid 
papillary carcinoma and intraductal papillary carcinoma, are classified separately and have a 
complex histopathological appearance and an indolent clinical behaviour85.  
1.5.3 Histological grade 
Morphologic assessment and tumour grading are part of the histopathological diagnostic work-
up of invasive breast carcinomas. A tumour’s histological grade is based on the assessment of 
tubule formation (glandular differentiation), nuclear pleomorphism and mitotic counts. The 
first described method for tumour grading by Bloom and Richardson was later modified by 
Elston and Ellis86, 87. Tumour grade is a powerful prognostic factor in invasive breast cancer88, 
89 and is routinely assessed for all invasive breast tumours by manual counting mitoses that 
together with tubule formation and nuclear pleomorphism gives the tumour Nottingham 
histological grade (NHG). Mitotic activity is assessed by counting mitoses; until recently in 10 
high-power fields, but since the latest WHO recommendations of 2019, mitoses are counted 
within a defined area in mm2 85. Accurate mitotic counts rely on optimal tissue fixation and 
preparation. Each of the three characteristics is given a numerical score of 1 to 3. These three 
scores are added to a total score (3 to 9) and final tumour grading of 1 to 3. A higher grade 
reflects a more aggressive and poorly differentiated tumour. The reproducibility of low (NHG 
1) versus high grade (NHG 3) is relatively sufficient. However, the challenges in classification 
lie within the intermediate grade (NHG 2), comprising up to 50% of tumours. NHG 2 tumours 
are likely a include a mixture of low- and high-grade tumours and provide limited clinical 
significance90, 91. In several other tumour types, such as squamous intraepithelial neoplasia of 
the lower anogenital tract and gastrointestinal adenoma, the three-tier classification of grading 
has been omitted and tumours are dichotomised by a two-tier grading into low- and high-grade 
dysplasia92, 93. Furthermore, gene expression studies have shown that grade better reflects “the 
molecular make-up of breast cancer” than lymph-node status or tumour size94, 95. 
1.5.4 TNM classification system and tumor stage 
Apart from patient age, tumour grade, histological subtype, margin status, and lymphovascular 
invasion, the most important prognostic factor is still the stage of the disease, which is captured 
in the TNM classification system of tumours of the breast and comprises primary tumour size 
(T), regional lymph node involvement (N), and spread to distant metastatic sites (M). The T, N 
and M are combined into stages 0-IV96, 97. Both clinical TNM (cTNM) and pathological TNM 
(pTNM) are evaluated for each breast cancer. Clinical stage is based on physical examination 
and radiological studies (T, N, M), whereas pathological stage is based on histopathological 
examination of surgical tumour specimen (T) and lymph nodes (N). However, M is generally 
determined by radiology findings and in some cases by FNAC or CNB diagnosis. Only pTNM 
will be discussed below. Tumour size is classified into T1 (£2cm), T2 (>2cm but £5cm), T3 
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(>5cm), and T4 (tumour extending into chest wall and/or skin). Nodal involvement is divided 
into N0 (no regional lymph node metastasis or isolated tumour cells), N1 (micrometastasis or 
metastasis in 1-3 ipsilateral lymph nodes), N2 (metastasis in 4-9 ipsilateral lymph nodes) and 
N3 (metastasis in ³10 lymph nodes). The presence of distant metastasis is classified as M1 and 
their absence of metastases as M0; most breast cancers may be defined as Mx (distant 
metastasis status unknown) since organ imaging for distant metastasis is not included in the 
work-up of most breast cancer cases today.  
Up to 50% of breast cancer patients present as stage I and only 5% as stage IV disease98. This 
can be reflected in the component of stage, where tumour size and nodal involvement are tightly 
correlated; e.g. 19% of pT1 tumours present with lymph node metastasis and 1% with distant 
metastasis, whereas pT3 tumours are associated with more frequent nodal (40%) and distant 
(10%) metastasis. In the recent AJCC TNM classification system, anatomical TNM 
information is combined with tumour-intrinsic biology into a ‘breast cancer prognostic stage’97. 
Apart from T, N and M, predictive biomarkers (ER, PR and HER2, see section 1.6) and grade 
are included for the stratification of outcome prediction. 
1.5.4.1 Staging of residual tumour after neoadjuvant therapy 
Similarly, classification of neoadjuvantly treated tumours is described using ypTNM, e.g. a 
resection of a primary tumour following neoadjuvant chemotherapy with a residual tumour size 
of 25 mm and two residual positive axillary lymph nodes without known distant metastases 
would be classified as ypT2N1M0. 
Pathological staging of residual tumour burden is crucial for the evaluation of the effect of 
neoadjuvant therapy. Pathological complete response (pCR) has been used extensively as an 
endpoint in neoadjuvant trials, and is associated with better prognosis99, especially for HER2-
positive and triple-negative tumours100, 101. pCR is defined as no residual invasive tumour in 
the breast and axillary lymph nodes (ypT0/tisN0)102. However, when complete response is not 
achieved, the residual tumour burden may vary from no change in tumour cellularity to a 
marked disappearance with only remaining clusters or dispersed tumour cells, which has until 
recently been classified as partial pathological response according to the Miller-Payne grading 
system, which estimates the decrease in cellularity102. The current WHO classification of breast 
tumours recommends the standardised evaluation of residual cancer burden (RCB), which 
considers the size of the tumour bed, the percentage of residual invasive cancer or DCIS, the 
number of residual positive lymph nodes and the size of the largest metastasis85, 103. These 
parameters are used to calculate an RCB index, and one of the four risk scores (RCB-0 to RCB-
III) is determined, which provides prognostic information across different biological breast 
cancer subtypes104.  
1.6 PREDICTIVE AND PROGNOSTIC BIOMARKERS 
Biomarkers defined as measurable indicators of normal physiological processes, specific 
disease states or pharmacological responses, are widely used in oncology105. A prognostic 
biomarker provides information on the likelihood of a clinical event, e. g. recurrence or 
   13 
progression of disease, regardless of therapy or after standard therapy106, 107. A predictive 
biomarker correlates to the likelihood of benefit from a specific clinical intervention, or the 
differential outcomes of several interventions, also including toxicity. Such a biomarker can 
also be used as a target for therapy107. Several biomarkers may provide both prognostic and 
predictive information.  
In breast cancer, established prognostic clinicopathological factors are age, tumour size, lymph 
node status, disease stage, histological grade, ER, PR, HER2 and the proliferation-associated 
nuclear protein Ki67. Of these, the predictive single-molecule biomarkers ER, PR and HER2 
have been used to identify patients eligible for targeted therapy for the past decades108. Ki67, 
however, is still one of the most controversial biomarkers in breast cancer (see section 1.6.3). 
Furthermore, several multigene expression assays have entered clinical practice and provide 
additional prognostic and predictive information (see section 1.7.7). 
As patient demand for personalised breast cancer therapy grows, we face an urgent need for 
more precise biomarker assessment and more accurate histopathologic breast cancer diagnosis 
to make better therapy decisions. In routine management of invasive breast cancer, analysis of 
the prognostic and therapy-predictive biomarkers ER, PR, HER2 and in some countries Ki67, 
is paramount77, 109-113. Today’s immunohistochemistry (IHC)-based methods for biomarker 
assessment, however, struggle with intra- and interobserver variability, which hampers its 
reproducibility. This is especially evident for Ki67114, 115. Since treatment decisions are based 
on these IHC-determined biomarkers, accurate assessment is essential. According to 
international guidelines ER, PR, HER2 and Ki67 should be analysed on the surgical tumour 
specimen or on a preoperative core biopsy12, 72, 74. 
1.6.1 Oestrogen and progesterone receptors 
The correlation between hormones and breast cancer development was first recognised more 
than a century ago116. Oestrogen receptors belong to the nuclear receptor superfamily117. The 
first main receptor for oestrogen was discovered in the 1950’s by Jensen and colleagues118, 119 
and was later named ERa, which was cloned in 1986120, 121. The second receptor for oestrogen, 
ERb, was discovered and cloned in 1996 by Gustafsson and colleagues122. ERa is encoded by 
the gene ESR1 located on chromosome 6q, whereas ERb is encoded by ESR2 on chromosome 
14q123, 124. The structure of the two receptors shows several similarities, and both ERa and ERb 
bind to oestrogen with similar affinity.  
The central hub in oestrogen signalling and the target for endocrine therapy is ER, a ligand-
activated transcription factor that binds and activates hundreds of target genes in response to 
ligand activation or growth factor signalling125. In the normal breast, ER signalling stimulates 
the growth of epithelial cells. Approximately 80% of all breast tumours express ERa, which is 
the clinically used biomarker predicting response to endocrine therapy126-128. Furthermore, co-
expression of PR through the ER-induced gene PGR is considered a positive response factor129. 
The prognostic and predictive role of ERb in breast cancer is still unclear130, 131. 
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PR is foremost considered a prognostic marker, independent of ER expression, and not 
predictive132. The predictive role of PR status is not fully understood; there are studies 
demonstrating that the role of PR may not be of as high importance as ER133, 134, and others 
showing that PR alone provides additional value135.  
Tumour expression of ERa, here referred to as only ER, and PR is determined by IHC staining, 
and scored through manual estimation of the percentage of positively stained nuclei across the 
whole tumour section. ER and PR status should be determined on all invasive breast tumours 
and recurrences. According to international guidelines, tumours with ³1% ER and PR are 
considered positive, and these patients should be considered for endocrine therapy. Tumours 
expressing less than 1% of tumour cells staining for ER or PR have internationally been 
considered negative, lacking benefit from endocrine therapy136. The percentage level, however, 
may provide valuable predictive and prognostic information regarding treatment strategies. In 
recent guidelines tumours expressing ER 1-10% (low-positive) have been highlighted74, 137. 
Tumours with ER low-positive expression are a heterogeneous group that have shown 
molecular features and clinical outcome more resembling triple-negative breast cancer138-140. 
Limited data on benefit from endocrine therapy in ER low-positive tumours render clinical 
challenges74. In clinical practice, the Swedish guidelines have for several years considered ER 
positivity as ³10% ER expression indicating a benefit from endocrine therapy12, 109. 
1.6.2 Human epidermal growth factor receptor 2 
Human epidermal growth factor receptor 2 (HER2), encoded by the proto-oncogene ERBB2 
(also referred to as HER2) located on chromosome 17, is a tyrosine kinase receptor located on 
the cell surface141, 142. The neu oncogene is the rodent homologue to HER2143, 144. HER2 is a 
member of the HER (ErbB) family of epidermal growth factor receptors (EGFRs) which is 
involved in normal cell growth, proliferation and survival145, 146. Receptor activation involves 
a ligand-induced receptor dimerisation (homo- or heterodimerisation) and subsequent 
activation of the intrinsic tyrosine kinase leading to initiation of downstream signalling 
pathways through the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated 
kinase (ERK) proliferation pathway and/or the phosphoinositide 3-kinase (PI3K)/protein 
kinase B (Akt) prosurvival pathway147-150. Apart from HER2 gene amplification and 
overexpression of the protein, the HER2 protein can heterodimerise with other members of the 
HER family (HER1, HER3 and HER4)149, illustrated in Figure 4.  
Amplification of the HER2 oncogene in breast cancer was first described by Slamon and 
colleagues in 1987151. HER2 gene amplification and/or receptor overexpression occurs in 10-
15% of breast cancers, and is associated with poor prognosis and a more aggressive cancer 
phenotype if untreated151-155. The monoclonal antibody trastuzumab, which targets the HER2 
protein was introduced almost two decades ago156 and since then the prognosis for HER2-
positive breast cancer has dramatically improved157, 158. HER2 is thereby a prognostic marker 
for aggressive tumours and a predictive biomarker for therapeutic response. HER2 
overexpressing and/or gene amplified tumours is also found among subsets of gastro-
oesophageal and endometrial cancers and associated with poor prognosis159-161.  
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Figure 4. The HER family and HER2 signalling pathways. Receptor activation involves a ligand-
induced receptor dimerisation (homo- or heterodimerisation) and subsequent activation of the intrinsic 
tyrosine kinase leading to initiation of downstream signalling pathways through the MAPK/ERK 
proliferation pathway, and/or the PI3K/Akt prosurvival pathway. HER2 receptor activation occurs 
through homodimerisation or heterodimerisation with HER1, HER3 or HER4. Created with 
Biorender.com. 
Pathological assessment of HER2 status is a crucial part of breast cancer diagnostics and 
determination of HER2 status is recommended for all stages of invasive breast cancer, as well 
as at disease recurrence72, 73, 155, 162. There are several available methods for determining HER2 
status at a protein, RNA and DNA level163. In routine pathology, overexpression of the HER2 
protein is evaluated by the membranous IHC staining of tumour cells and the scoring is based 
on the degree of circumferential or only partial membrane staining and its intensity. According 
to guidelines73, 162, an IHC score is given between 0 (no staining) to 3+ (strong staining). IHC 
scores 0-1+ are referred to as negative HER2 status, whereas score 3+ is considered positive. 
An IHC score of 2+ is considered equivocal and additional in situ hybridisation (ISH) should 
be performed to confirm amplification. HER2 gene amplification is determined as HER2 copy 
numbers by a DNA probe integrated to an ISH detection platform. Fluorescent and 
chromogenic ISH have been used during different time periods and lately mostly replaced by 
silver-enhanced ISH. The American Society of Clinical Oncology (ASCO)/College of 
American Pathologists (CAP) HER2 testing guideline currently recommends the use of dual-
probe ISH assays instead of singe-probe assays162.  
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In dual-probe ISH assays, the locus-specific probe for HER2 detects ERBB2 and the 
chromosome enumeration probe 17 (CEP17) detects the centromeric region of chromosome 
17164. The HER2/CEP17 ratio is determined by assessment of copy numbers for HER2 and 
CEP17, respectively. In rare cases, chromosome 17 polysomy may occur, where the tumour 
cells have increased number of chromosome 17 regardless of HER2 amplification165-167. The 
ASCO/CAP HER2 guidelines for breast cancer were first published in 2007, revised in 2013 
and included significant updates in 2018 especially for the groups of less common ISH results73, 
162, 168. Tumours with HER2 IHC score 2+ require reflex testing with ISH. The diagnostic 
algorithm for evaluation of HER2 ISH presented by ASCO/CAP 2018 guidelines divides 
tumours into five groups (Group 1-5) based on HER2/CEP17 ratio and average HER2 copy 
numbers162. Tumours with a ratio ³2.0 and average HER2 copies/cell of ³4.0 (group 1) are 
defined as ISH positive whereas those with a ratio <2.0 and average copies/cell <4.0 (group 5) 
are ISH negative. These two groups comprise up to 95% of HER2 tested cases in a 
population162. The less common scenarios include tumours with a ratio ³2.0 and <4.0 
copies/cell (group 2), ratio <2.0 with ³6.0 copies/cell (group 3) or with ³4.0 but <6.0 copies/cell 
(group 4). Group 2-4 required additional work-up and correlation to IHC. In summary, only 
tumours with HER2 IHC 3+, or 2+ along with ISH group 1 or 3 are determined HER2 positive. 
The clinical significance of HER2 “equivocal” variants remains, however, unclear. 
1.6.3 Proliferation-associated marker Ki67 
The tumour’s ability to sustain proliferative activity is one of the hallmarks for cancer and the 
most fundamental trait of cancer19, 20. Apart from mitotic count, the proliferation-associated 
nuclear protein Ki67 is assessed by IHC for evaluation of a tumour’s proliferative activity. 
Ki67 is expressed in all proliferating cells and is not specific for breast tissue. Ki67 is 
predominantly expressed in all active phases of the cell cycle other than G0, including 
apoptosis, and is therefore a rather unspecific marker for mitotic activity169. The exact function 
of Ki67 is not completely understood, although studies suggests that Ki67 plays a crucial role 
in ribosomal RNA synthesis170, 171. 
IHC assessment of Ki67 is the most widely used method for proliferation in clinical practice 
for breast cancer (Figure 5). Ki67 has been demonstrated to be a prognostic biomarker in early 
breast cancer, but there are still uncertainties regarding its role in clinical breast cancer 
management172-174. There is strong evidence for a biological relationship between Ki67 and 
prognosis, but the cut-off to distinguish high from low proliferation shows variation from 1% 
to 28.6% in larger studies, which limits the clinical applicability175. Furthermore, Ki67 has 
shown prognostic value in patients with NHG 2 tumours, thus dividing these tumours into two 
different prognostic groups176, 177. 
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Figure 5. Breast tumours with low (a), intermediate (b) and high proliferation (c) by Ki67 
immunohistochemistry staining (clone 30-9). 
Inconsistent Ki67 cut-offs result in varying distributions of luminal A- and B-like tumours 
(described in section 1.7 and 1.8) in different pathology laboratories thus effects the decisions 
for chemotherapy77. The International Ki67 in Breast Cancer Working Group (IKWG) agreed 
that IHC of Ki67 was the current assay of choice for proliferation assessment in pathology 
specimen, although recognising the poor agreement on its specific clinical use. The working 
group proposed a concept to standardise the interpretation of Ki67, including number of cells, 
tumour region of interest and analytical validity178. However, Ki67 is prone to inter- and 
intraobserver variability, further hampering its reproducibility114, 115. In addition, different 
assessment methods are still being used, from eyeball estimation, counting up to 1000 tumour 
cells to automated digital image analysis172. Furthermore, the application of Ki67 and its cut-
off for decision making is considered unreliable outside experienced laboratories with own 
reference data178. With interlaboratory discordance and lack of standardised protocols, neither 
the IKWG nor the St Gallen expert deliberations have settled recommendations for Ki67 in 
routine oncology110, 178, 179. There is no consensus protocol regarding what tumour region to 
assess for highest biological or clinical importance. In international recommendations 1000 
cells with a minimum of 500 cells should be counted77, 178, whereas the Swedish guidelines 
recommend Ki67 scoring of 200 cells in a hot spot region12. The definition of a hot spot is an 
area in which Ki67 nuclear staining is particularly prevalent, but this approach varies across 
studies178. In addition, the ASCO guidelines recommend against the use of Ki67 for guiding 
therapy due to insufficient evidence180. Digital image analysis (DIA) is suggested to improve 
reproducibility181-183. Recently, the IKWG suggested automated scoring methods for Ki67 
based on reproducibility but sill acknowledges the need for standardisation and assessment of 
clinical validity182, 184. 
1.6.4 Phosphohistone H3 
Moreover, in contrast to the proliferation-associated biomarker Ki67, phosphorylation of 
histone H3 (PHH3) occurs exclusively in late G2 and M-phase. PHH3 is involved in chromatin 
condensation and crucial for entering mitosis, and a more recently described marker for 
proliferation in breast cancer. Thus, it is both in theory and practice a very specific marker for 
A B C 
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mitotic activity, and high PHH3 has been associated with poor prognosis185-188. This approach, 
however, has not been introduced in clinical practice. 
1.6.5 Tumour-infiltrating lymphocytes 
Tumour-infiltrating lymphocytes (TILs) are mononucleated lymphoid cells, which infiltrate 
the tumour and its surrounding stroma, reflecting the host immune response. Evaluation of 
tumour immune response is gaining importance as prognostic and predictive markers in several 
solid tumour types as the implications for immunotherapies are expanding189. Increasing data 
has shown that TILs are associated with increased response to neoadjuvant therapy and 
improved outcome after adjuvant chemotherapy in triple-negative and HER2-positive breast 
cancer190-193. Routine assessment of TILs in triple-negative tumours has now been incorporated 
in the most recent guidelines12, 194. 
Visual TIL assessment on HE sections is a prognostic marker in breast cancer, and efforts have 
been made to increase reproducibility and standardisation195. Standardised methods for 
quantification of TILs have been proposed by Salgado et al. from the International TILs 
Working Group196. Stromal TILs are scored by estimating all mononuclear lymphocytes within 
the stroma between the areas of invasive tumour as the percentage of the stromal area196. 
Computer-aided diagnosis will provide an important tool for increased reproducibility. In a 
study on melanoma, automated TIL scoring showed robust and independent prognostic 
value197. An automated deep learning approach for TIL scoring in breast cancer has recently 
demonstrated correlations with gene expression data and survival outcome198. 
1.6.6 Programmed death-ligand 1 (PD-L1) 
PD-L1 also known as B7-H1, is a ligand to the inhibitory checkpoint molecule PD-1 present 
on activated T cells, B cells and myeloid cells. Upregulation of PD-L1 on tumour cells is 
associated with aggressiveness and evasion from the host immune system. Agents targeted at 
blocking PD-1/PD-L1, so called check-point inhibitors such as pembrolizumab and 
atezolizumab, have shown promising results in several solid tumours including metastatic 
triple-negative breast cancer199-202. In the ongoing I-SPY2 phase 2 trial, data recently showed 
that the addition of pembrolizumab to neoadjuvant chemotherapy doubled the estimated 
pathological complete response rates for triple-negative and ER-positive/HER2-negative early 
breast cancer203. In triple-negative breast tumours, PD-L1 expression is mainly present on 
tumour-infiltrating immune cells, and not on tumour cells, with the ability to inhibit anti-
tumour immune responses204. Recent results from the IMpassion130 trial demonstrated that 
PD-L1 expression on >1% of tumour-infiltrating immune cells was predictive of improved 
progression-free and overall survival in metastatic triple-negative breast cancer treated with 
atezolizumab combined with chemotherapy (nab-paclitaxel)204, 205. 
Therefore, IHC assessment of PD-L1 is required prior to determine eligibility to treatment with 
anti-PD-L1 antibodies. Of importance is that approved antibodies are used with corresponding 
scoring algorithms, so called companion diagnostics, which may vary depending on organ site 
and manufacturer. The only currently approved assay for breast cancer is the PD-L1 SP142 
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assay (VENTANA, Roche Diagnostics, Rotkreuz, Switzerland)204. The indications for check-
point inhibitors are rapidly evolving, and several new assays will most certainly emerge in 
clinical practice in the near future. 
1.6.7 Quality assurance of biomarkers 
Tumour biomarkers are not only used for prognosis and prediction, but have wide utility for 
differential diagnosis, monitoring and risk stratification. Regardless of use, quality assurance 
is of utmost importance. Analytic validity, clinical validity and clinical utility all need to be 
considered when recommending a biomarker test to guide treatment decisions206. The 
accuracy, reliability and reproducibility of a biomarker assay are parts of analytical validity. 
Clinical validity is the ability of a biomarker test to distinguish biologically or clinically 
different groups, e.g. if a positive test is associated with worse prognosis. If a biomarker test is 
judged to have clinical utility, it is unlikely that it would lack clinical validity206. 
Internal quality assurance of biomarker assays includes positive and negative control samples 
on the glass slide to assure accurate performance of the IHC staining, as well as accreditation 
of each laboratory performing the assay. The results from a biomarker test should be identical 
regardless of in which laboratory the assay was performed. To ensure this, participation in 
external quality assurance programmes are mandatory, such as the Nordic 
immunohistochemical Quality Control (NordicQC)207, the UK National External Quality 
Assessment Scheme155, 208 and CAP209. National cancer registries, such as the National quality 
registry for breast cancer database also provide continuous data of biomarker results across 
hospitals in Sweden13. 
As described above, the controversies regarding Ki67, are mainly due to concerns in analytical 
validity, and especially reproducibility114, 115, 179. Regarding HER2 status, both local and 
regional variations in HER2 positivity rates are evident, and continuous improvement strategies 
are important to limit false-negative and false-positive results13, 210, 211. As for other biomarkers, 
HER2 testing is influenced by pre-analytical and analytical factors, but also tumour features 
such as tumour heterogeneity211. 
1.7 MOLECULAR SUBTYPES OF BREAST CANCER  
Over the past decade, it has been established that breast cancer comprises a heterogeneous 
group of diseases with distinct molecular features212. Gene expression profiling of breast cancer 
has provided additional prognostic information to the standard clinicopathological 
assessment59, 213-215. The recognition of gene expression signatures and intrinsic subtypes based 
on global mRNA expression, as first described by Perou et al. in 2000, has provided promising 
alternatives for stratification of invasive breast tumours58, 59. Based on DNA microarray and 
hierarchical clustering, the intrinsic subtypes luminal A, luminal B, HER2-enriched, basal-like 
and normal-like have been widely investigated58-60, 214, 216, 217. Other rare subtypes include the 
claudin-low, interferon-rich and molecular apocrine subtype60, 214, 218, 219. The prediction 
analysis of microarray (PAM) 50 classifies breast tumours into four major intrinsic subtypes: 
luminal A and B, HER2 enriched and basal-like214. These molecular subtypes of breast cancer 
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and the correlation to clinicopathological features are illustrated in Figure 6. Several 
commercial multiparameter molecular marker assays have been developed for subtype 
classification and estimated risk of recurrence (described in section 1.7.7).  
 
Figure 6. Molecular subtypes of breast cancer and the correlation to clinicopathological features. 
HER2-E, HER2-enriched; HER2 Rx, HER2-targeted therapy; Hormone Rx, endocrine therapy. 
Adapted from WHO Classification of tumours 201985. 
1.7.1 Luminal A 
The luminal A and B subtypes of breast cancer are the most heterogeneous subtypes 
characterised by the expression of ER-associated genes, and together account for 70% of all 
breast tumours220. Luminal A tumours show a high expression of luminal epithelial genes, low 
expression of proliferation/cell-cycle related genes (e.g. MKi67) and have a good prognosis58-
60, 221. At a protein level, these tumours show high expression of ER and PR, but low Ki67 and 
HER2. The Luminal A subtype is a heterogeneous group of tumours and the most frequent 
somatic mutations include PIK3CA, GATA3, MAP3K1 and TP53 220. 
1.7.2 Luminal B 
The Luminal B subtype corresponds to approximately 20% of all breast cancers220. Luminal B 
tumours show higher expression of proliferation/cell-cycle related genes, have poorer 
prognosis and are less sensitive to endocrine therapy than luminal A tumours222. The major 
difference between luminal A and B subtypes is the expression of proliferation-associated 
genes, and thus Ki67 has been suggested to act as a surrogate marker for discrimination 
between the two subtypes223. Furthermore, luminal B tumours have been associated with high 
tumour grade (NHG 2-3), whereas luminal A tumours rarely are NHG 360. Luminal B tumours 
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exhibit a higher number of mutations including TP53, but similar GATA3 mutations and less 
PIK3CA and MAP3K1 mutations as compared with luminal A212. 
1.7.3 HER2-enriched 
HER2-enriched tumours are characterised by a high level of ERBB2 gene expression, ERBB2 
amplicon genes (e.g. GRB7) and receptor tyrosine kinases (e.g. FGFR4 and EGFR), and a low 
expression of luminal genes58, 224. The HER2-enriched subtype clinically best corresponds to 
ER-negative, HER2-positive tumours, effectively targeted with anti-HER2 therapies60, 225. The 
highest numbers of mutations are found within this tumour subtype, and include both TP53 and 
PIK3CA. However, the HER2-enriched subtype is not uniquely found among HER2 
overexpressing or ERBB2 gene-amplified tumours, but is also present within HER2-negative 
tumours226. Furthermore, it was recently shown that HER2-enriched tumours are more 
frequently found to have a high mRNA expression of ERBB2 and are associated with increased 
response to HER2-targeted therapy compared with those with low ERBB2 expression224. In 
addition, tumours with low ERBB2 expression comprised a variety of all molecular subtypes224. 
1.7.4 Basal-like 
The basal-like subtype has the most distinct genomic profile containing genes (e.g. c-KIT, 
FOXC1 and P-cadherin) characteristic of basal epithelium; on the DNA level, it shows a high 
prevalence of TP53 mutations60. Basal-like tumours mainly correspond to the triple-negative 
phenotype, although a small proportion of ER-positive tumours may also display a basal-like 
phenotype58, 59, 217,221. In addition, 2-17% of basal-like tumours feature HER2/ERBB2 
overexpression or amplification226. Rare histological subtypes such as medullary and adenoid 
cystic carcinoma can be found among basal-like tumours. 
Triple-negative tumours, lacking ER, PR and HER2 expression, are often high-grade tumours 
with poor prognosis227. Unsupervised analysis of triple-negative tumours revealed several 
subtypes, such as luminal androgen receptor, mesenchymal, basal-like immunosuppressed and 
basal-like immune-activated, each with different prognoses228, 229. These distinct molecular 
subgroups may reveal future targets for precision medicine and need further investigation. 
1.7.5 Normal-like 
The normal-like subtype comprises about 5-10% of all tumours, including both ER-positive 
and ER-negative tumours. The classification of normal-like is thought to be a mixture of normal 
breast tissue and tumour or a group of basal-like tumours without expression of proliferation 
associated genes214, 217, 218. The clinical significance of this subtype is not fully understood. 
1.7.6 Claudin-low 
The biological and clinical significance of the more recently identified subtype of claudin-low 
tumours is still somewhat uncertain218. The claudin-low subtype is a heterogeneous group and 
recent findings have identified three distinct subgroups within the claudin-low subtype each of 
which emerge from different cells of origin230. These tumours show a characteristically low 
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gene expression of tight junction proteins (claudin 3,4 and 7) and E-cadherin231. The claudin-
low subtype has a low expression of luminal and proliferation-related genes, but overexpresses 
immune response genes, which suggests tumours with high immune infiltration231. They are 
also enriched in epithelial-to-mesenchymal transition and cancer stem cell features. The 
claudin-low subtype is associated with poor prognosis and is over-represented among 
metaplastic and medullary carcinoma231. Claudin-low together with basal-like tumours 
constitute the majority of triple-negative breast tumours230.  
1.7.7 Prognostic multigene signatures 
With the increasing demand for personalised precision medicine, multiple commercial gene 
expression-based assays and risk stratification analyses have been developed and are now 
available. Gene expression analysis can improve stratification of patients and select patients 
who may actually benefit from cytotoxic chemotherapy. For patients >50 years with ER-
positive HER2-negative and lymph node-negative breast cancer, valuable prognostic 
information can be attained from gene expression analysis for risk categorisation of the tumour 
prior to choice of chemotherapy206. Several multigene signature assays show robust prognostic 
clinical utility in identifying low-risk node-negative early breast cancer without benefit of 
chemotherapy232-235. Similar prognostic results have been demonstrated for patients with 
limited lymph node positivity (1-3 lymph node metastases) with Prosigna and EndoPredict236-
239. With the collected evidence, the current recommendation is to omit chemotherapy in ER-
positive/HER2-negative cases with low-risk multigene signatures and limited lymph node 
involvement234, 240, 241. The following section will cover the evidence-based gene expression 
assays available for clinical use in Europe. A principal overview of multigene signature assay 
is illustrated in Figure 8. 
1.7.7.1 Oncotype DX recurrence score 
Oncotype DX Breast Recurrence Score® (Exact Sciences Corp., Madison, USA) is a 
quantitative reverse transcriptase polymerase chain reaction (RT-qPCR)-based 21-gene 
signature assay that generates a recurrence score between 0 and 100, indicating the likelihood 
of distant metastasis232, 235. There is a large amount of data supporting the prognostic value of 
Oncotype DX, and it is the most validated multigene signature test241-243. The prospective trial 
TAILORx was specifically designed to investigate its clinical utility in ER-positive/HER2-
negative and node-negative breast cancer240. Secondary data analysis showed that only 
premenopausal patients with a recurrence score of 16-25 had a decreased risk for distant 
metastasis when treated with chemotherapy in addition to endocrine therapy, compared with 
endocrine therapy alone244. There is, however, limited evidence for the use of Oncotype DX 
recurrence score to identify low-risk cases among lymph node-positive patients, who could be 
spared chemotherapy245. Results from the ongoing randomised trial RxPONDER may further 
clarify this (ClinicalTrials.gov Identifier: NCT01272037).  
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Figure 7. Principal overview of molecular gene expression signature assays. Adapted from van’t Veer 
et al. 2005247. Created with Biorender.com. 
1.7.7.2 PAM50-based Prosigna risk of recurrence score 
As mentioned above, the PAM50 assay classifies tumours into luminal A, luminal B, HER2-
enriched and basal-like. The PCR-based PAM50 signature was combined with clinical 
information into a model that provides a prognostic risk of recurrence score214. Based on this, 
Prosigna® (NanoString Technologies, Seattle, USA) was developed, which is a PAM50-based 
classifier of risk of recurrence score that is optimised for formalin-fixed paraffin-embedded 
(FFPE) material and utilises the NanoString nCounter DX analysis system instead of PCR 
analysis for improved accuracy of mRNA expression238. The PAM50-based risk of recurrence 
score has demonstrated robust prognostic value in ER-positive/HER2-negative breast cancer, 
and is currently the only multigene signature assay that provides molecular subtypes214, 236, 239. 
Sestak et al. recently compared six multigene signatures among node-negative ER-
positive/HER2-negative patients and found that PAM50 risk of recurrence, followed by Breast 
Cancer Index and EndoPredict provided the strongest prognostic value for overall and distant 
recurrence246. The PAM50-based Prosigna assay and risk of recurrence score are currently used 
in clinical practice in Scandinavia.    
1.7.7.3 MammaPrint 
MammaPrint® (Agendia, Amsterdam, the Netherlands) is based on the Amsterdam 70-gene 
signature and utilises both FFPE and fresh-frozen tumour material. Based on microarray 
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expression profiling, the tumour is classified as posing a low or high risk of recurrence213, 234, 
247. The prognostic value of MammaPrint has been validated, although not as extensively as 
Oncotype DX242. The clinical utility of MammaPrint was further investigated in the 
MINDACT trial, but no predictive value for choice of chemotherapy could not be 
demonstrated234.  
1.7.7.4 EndoPredict 
EndoPredict® (Myriad Genetics, Salt Lake City, USA) is a 12-gene expression assay that 
provides a score from 0 to 15 along with low or high risk for early and late distant recurrence 
in ER-positive/HER2-negative early breast cancer248, 249. The prognostic value of EndoPredict 
has been demonstrated in both node-negative and node-positive ER-positive/HER2-negative 
breast cancer237, 248, 250, 251. 
1.8 IMMUNOHISTOCHEMICAL SURROGATE SUBTYPES  
With reduced costs, gene expression profiling is becoming more integrated in routine 
diagnostics of breast cancer. However, such assays are not universally accessible, especially 
not in low-income countries. The molecular intrinsic subtypes can be recapitulated using the 
IHC measurements of ER, PR, HER2 and Ki6777, 110, 111, 221. Surrogate subtypes are defined as 
luminal A-like, luminal B-like (HER2 negative), luminal B-like (HER2 positive) and triple 
negative. 
1.8.1 Surrogate subtype classification  
1.8.1.1 The international St Gallen consensus recommendations 
The initial Ki67 cut-off set to 14% to dichotomise luminal B from luminal A tumours was 
established by Cheang et al.223. Furthermore, the 2011 St Gallen International Expert 
Consensus adopted the gene expression profiling subtypes and proposed IHC-based surrogates, 
which included Ki67 (14% cut-off) to distinguish luminal B-like from luminal A-like 
tumours111. With increasing evidence, the 2013 St Gallen panel presented clinicopathologic 
surrogate definitions of the intrinsic subtypes, with emphasis on the luminal subtypes and their 
definitions77, suggesting that either high Ki67 or low PR may distinguish between luminal A-
like and luminal B-like (HER2 negative) tumours. However, the controversies regarding Ki67 
cut-offs between high and low values remained, and laboratory specific values were 
recommended, although a ³20% threshold was suggested for high Ki67 status. Furthermore, 
Prat et al. demonstrated the prognostic value of PR and the use of a PR cut-off of ³20% to 
define luminal A-like cancer132. In addition, the St Gallen recommendations suggested type of 
systemic treatment for each defined surrogate subtype in 2013. The surrogate subtype 
definitions of the St Gallen 2013 were as follows:  Luminal A-like: ER positive, PR positive, 
HER2 negative and Ki67 low; Luminal B-like (HER2 negative): ER positive, HER2 negative 
and Ki67 high or PR negative; Luminal B-like (HER2 positive): ER positive, HER2 positive 
and any Ki67 or PR; HER2 positive (non-luminal): HER2 positive and ER and PR absent; 
Triple negative: ER and PR absent and HER2 negative (Table 1)77, 132.  
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In the 2015 St Gallen expert consensus, a Ki67 cut-off within the range of 20-29% was accepted 
to distinguish luminal B-like disease110. In recent recommendations, tumour grade in addition 
to Ki67 was suggested to distinguish between luminal A and B-like tumours252. Adding NHG 
to St Gallen 2013 surrogate subtype classification of ER-positive/HER2-negative tumours has 
demonstrated independent prognostic information in Swedish cohorts253; ER-positive/HER2-
negative tumours of NHG 1 had similar prognosis as luminal A-like tumours, whereas NHG 3 
tumours had prognosis similar to luminal B-like tumours253.  
The current European Society for Medical Oncology guidelines, however, refer to the St Gallen 
2013 surrogate definitions of intrinsic subtypes72. The expert consensus regarding early breast 
cancer from the 16th St Gallen International Breast Cancer Conference held in 2019 
recommends gene expression assays for distinguishing luminal A from B tumours, and raises 
concerns regarding the lack of validity for basing treatment decisions (adjuvant chemotherapy) 
on only IHC-based surrogate subtypes194. 
Table 1. Surrogate subtype classification adapted from the St Gallen 2013 
consensus77, 132. 
Intrinsic surrogate subtype Clinicopathologic surrogate definition 
    
Luminal A-like ER positive (³1%) and PR positive (³20%; Prat 2013) 
 and 
 HER2 negative 
 and 
 Ki67 low (<20%; panel consensus) 
  
Luminal B-like (HER2 negative) ER positive (³1%) 
 HER2 negative 
 and at least one of: 
 Ki67 high (³20%; panel consensus) 
 PR negative or low (<20%; Prat 2013) 
  
Luminal B-like (HER2 positive) ER positive (³1%) 
 HER2 over-expressed or amplified 
 any Ki67/PR 
  
HER2 positive (non-luminal) HER2 over-expressed or amplified 
 ER and PR absent (<1%) 
  
Triple negative (ductal) ER and PR absent (<1%) 
 HER2 negative 
 
1.8.1.2 Swedish national guideline recommendations 
Congruence between IHC-based surrogate subtypes and the gene expression-based intrinsic 
subtypes is of utmost importance with regard to clinical implementations. In 2014 
Maisonneuve and colleagues introduced an intermediate Ki67 group and demonstrated the 
prognostic value of PR in this group254. The most recent Swedish national guidelines adopted 
   26 
this work and recommend a three-tier classification of Ki67 into low, intermediate and high 
proliferation for ER-positive/HER2-negative tumours, with the use of laboratory-specific Ki67 
cut-offs (Figure 8)12. In addition, tumours showing intermediate Ki67 levels, PR positivity 
³20% is required for luminal A-like disease. The major impact of these distinctions between 
luminal A and B-like tumours is the clinical implication for utility of adjuvant chemotherapy254. 
As mentioned in section 1.6.1, the Swedish classification for ER positivity is ³10% as opposed 
to ³1%, which is generally considered positive internationally136.  
The concordance rate between PAM50 molecular subtype and IHC-based surrogate 
classifications by St Gallen 2013 is rather poor (62%, kappa 0.30) regarding ER-
positive/HER2-negative tumours but can be somewhat improved by applying the Maisonneuve 
classifications (66%, kappa 0.35)254, and as shown in a Swedish population-based cohort even 
further improved by using a grade-based classification for distinguishing luminal A from 
luminal B tumours (70%, kappa 0.41)255. Furthermore, by only classifying NHG 1-2 as luminal 
A-like and NHG 3 tumours as luminal B-like, the agreement with PAM50 subtype (luminal A 
and B) could be even increased (80%, kappa 0.46)255. Apart from grade the three-tier Ki67 
groups are incorporated into the current Swedish national guidelines, as illustrated in Figure 8 
and Table 2. 
 
Figure 8. Flow diagram for surrogate subtype classification according to the Swedish guideline 
recommendations. ER-positivity defined as ER ³10%. Laboratory-specific cut-offs are used for 
determiningnlow, intermediate and high Ki67 groups. Gene expression analysis is recommended for 
patients aged > 50 years when surrogate subtype will have effect on treatment decisions. Adapted from 
the 2020 National care program for breast cancer12. 
 
   27 
Table 2. Surrogate subtype classification adapted from the 2020 Swedish national 
guidelines12. 
Intrinsic surrogate subtype Clinicopathologic surrogate definition 
    
Luminal A-like ER positive (³10%) 
 HER2 negative 
 and 
 Ki67 low° and NHG 1-2* 
 or 
 Ki67 intermediate and PR ³20% and NHG 1-2*  
  
Luminal B-like (HER2 negative) ER positive (³10%) 
 HER2 negative 
 and  
 Ki67 high° and NHG 2-3* 
 or 
 Ki67 intermediate° and PR <20% and NHG 2-3* 
  
Luminal B-like (HER2 positive) ER positive (³10%) 
 HER2 over-expressed or amplified 
 any Ki67/PR/NHG 
  
HER2 positive (non-luminal) HER2 over-expressed or amplified 
 ER and PR negative 
  
Triple negative (ductal) ER negative (<10%) and PR negative (<10%) 
 HER2 negative 
°Ki67 scoring according to laboratory-specific cut-offs for low, intermediate and high Ki67. 
*Tumours with e.g. NHG 1 and high Ki67 or NHG 3 and low Ki67 should warrant re-
evaluation. 
 
 
1.9 GENOMIC PROFILING OF BREAST CANCER 
Evidently, there is an increasing demand for personalised cancer diagnostics and treatment. 
DNA and RNA sequencing-based molecular profiling of tumours holds potential to provide 
patients and clinicians with information on tumour characterisation and genomically matched 
therapy256, 257. High-throughput massively parallel NGS has rapidly changed the content and 
throughput of sequencing-based diagnostics. RNA sequencing-based molecular profiling of 
breast cancer could be used to predict the current routine biomarkers ER, PR and HER2. One 
of the great advantages provided by sequencing-based diagnostics is the improvement of 
models for patient stratification, such as a transcriptomic grade model, and additional 
information on targetable somatic alterations258. Sequencing of single genes such as EGFR and 
KRAS in non-small cell lung cancer is now part of routine pathology. However, a broader 
approach is needed to identify therapy-predictive mutations and structural variants. Several 
university hospitals, Karolinska University Hospital included, are on their way to design in-
house gene panels for pan-cancer testing for targeted drugs. The nation-wide initiative 
Genomic Medicine Sweden is developing a national Swedish gene panel for genomic profiling. 
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With the advances in PI3K inhibitors, clinical practice will require PIK3CA mutation analysis, 
and sequencing panels need to be available (see section 1.11.6). 
Zehir et al. recently demonstrated the application of prospective clinical sequencing of solid 
tumours using MSK-IMPACT, a hybridisation capture-based NGS panel, in order to guide the 
use of genomically matched therapies259. Notably, in the SHIVA trial, investigating the use of 
molecularly targeted “personalised” agents outside their indications and based on tumour 
molecular profiling, they could not confirm any improved patient outcome compared to routine 
treatment of choice260. To date, off-label use of molecularly targeted agents is discouraged. The 
true clinical utility of molecular profiling is still uncertain and further clinical trials are required 
to prove the efficacy of molecular targeted therapies. 
1.10 DIGITAL IMAGE ANALYSIS  
Computerised image analysis in histopathology of breast tumours holds promise to improve 
breast cancer diagnosis, including reproducibility for biomarkers and novel methods for 
precision pathology261. However, there is controversy about how imaging should be 
implemented110, 262. The development of systems of digital image analysis (DIA) has shown 
excellent reproducibility and accuracy, though so far in subsets with individual biomarkers or 
smaller populations263-266. There is an expanding industry and competition for digital pathology 
image analysis solutions, and several available software solutions for breast pathology have 
emerged. The majority of the commercial solutions operate on input from scanned whole-slide 
images. The focus of DIA has until recently been on quantifying biomarkers by IHC. Apart 
from biomarker analysis, automated image analysis has e.g. been demonstrated to eliminate 
negative metastasis-free sentinel node biopsy images stained by IHC pancytokeratins, as a 
screening method267. The most exciting advances in digital pathology have been reached using 
artificial intelligence (AI) and machine learning approaches261, 268 (see section 1.10.4).   
Several pathology departments are adopting a digital work flow with whole-slide image 
scanning as an integrated part of the histology laboratory workflow, and the demand for 
advanced image analysis software is steadily increasing. The U.S. Food and Drug 
Administration recently approved the first whole-slide imaging system for digital surgical 
pathology269. Apart from routine diagnosis, digital pathology enables remote consultation and 
telepathology, interactive presentations of tumour features in multidisciplinary team 
conferences, enhanced histopathology education and research approaches. 
1.10.1 Image data acquisition 
To enable any kind of DIA, histopathological glass slides need to be digitised into an image 
file. Whole-slide scanners capture tissue slide images tile by tile or in a line-scanning manner, 
and assemble the tiles or lines to create a digital image of the tissue270. Modern scanners utilise 
incorporated tissue recognition to allow for efficient scanning and focus points that operate by 
continuous automatic refocusing. In parallel to a brightfield microscope, scanning can be 
performed in several magnifications. For most purposes scanning at x20 magnification is the 
standard for HE and IHC images. However, x40 magnification provides in-depth details 
   29 
required for e.g. ISH analysis or for training advanced machine learning models. Modern 
scanners have the capacity to load up to 400 slides and depending on magnification and 
scanner, scanning times vary from 30 seconds to minutes per slide 271. Regarding digitisation 
of cytological slides special considerations are needed to improve digital cytopathology272. 
Cytological slides are composed of three-dimensional cell groups, and for this, optimal z-axis 
scanning is required for accurate focus. The variety of cytological specimens result in direct 
smears, liquid-based cytology and cell blocks, all of which require different approaches272. 
With the rapid technological development, high-quality cytopathological whole-slide imaging 
is in the near future273. 
High-resolution viewing of digital slides, or whole-slide images, is both dependent on the 
resolution of the scanner as well as the resolution of the monitor. An image scanner at x40 
generally has a resolution of 0.25 µm/pixel and a 24-bit colour depth270. The file size of whole-
slide images often exceeds 1 GB, which poses challenges for storage capacity. In the 
digitisation of routine pathology workflows, not only the storage is an issue but also the time 
for archiving digital images. This needs to be both standardised and regulated across countries, 
and must follow patient data protection regulations.  
1.10.2 Image processing techniques 
A variety of image processing methods are used for pre-processing, nuclei detection, 
segmentation, separation and classification274. Whole-slide imaging reflects variations in tissue 
staining intensities and colours even better than glass slides. Colour differences may occur 
when the same tissue slide is digitised with different scanners or presented in different viewers 
and displays270 but there are several colour normalisation methods developed for both HE and 
IHC staining274, and colour deconvolution is one of the methodologies for normalisation275, 276. 
Other pre-processing steps that can be used to adjust for adverse conditions across several 
images (batches) are illumination normalisation, noise reduction and region of interest 
detection. 
For many histopathological applications, such as IHC counting and mitosis detection, optimal 
nuclei detection methods are important. For tumour grading, the quality of nuclei segmentation 
has profound impact. Nuclear heterogeneity and overlapping can be handled with nuclei 
separation methods. Furthermore, with the previous methods computed, nuclei features and 
classification generate more information required for e.g. tumour detection274. 
1.10.3 Software 
Several scanner systems also provide image viewing software. The basic features of viewers 
include efficient image overview with zoom features, annotation tools, and selections of 
regions for snapshots and exporting images. More advanced image analysis features are usually 
provided in locked pre-defined packages from vendors and can be integrated into the workflow. 
A freely available alternative is the ImageJ software, developed by the National Institute of 
Health, which thus pioneered the field of open source image analysis algorithms277. In 2017, 
the open source platform QuPath was developed, specifically designed to handle whole-slide 
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images, and also allowing researchers access to advanced open source algorithms278. In the 
following sections, two different software platforms, which were used in this thesis will be 
described in more detail. 
1.10.3.1 Visiopharm Integrator System 
Within the Visiopharm Integrator System (VIS) provided by Visiopharm A/S (Hoersholm, 
Denmark), a virtual double staining technique has been developed where a pancytokeratin-
stained tumour section is aligned with a parallel section IHC-stained for the biomarker of 
interest, e.g. Ki67 or PHH3. The Conformité Européenne (CE) In Vitro Diagnostic (IVD) 
approved algorithm application (so called APP) for tumour detection (PCK VDS APP) enables 
automatic precise biomarker analysis of tumour cells, omitting proliferating stromal cells and 
artefacts. Hereby, only epithelial cells are eligible for image analysis to determine the 
percentage of stained tumour cells expressing the specific biomarker (Figure 9). Depending on 
tissue and task, individual APPs are developed and then run for each image of biomarker279. 
Using the VIS with virtual double staining, Stålhammar et al., showed the advantages in 
congruence to gene expression assays and the prognostic power of automated image analysis 
compared to current manual methods of biomarker assessments280. Further APPs for specific 
tumour regions of interest have been developed and investigated on proliferation-associated 
biomarkers such as Ki67 and PHH3. Using the VIS and these applications, findings presented 
within my thesis project show that digital image analysis of Ki67 in hot spots outperforms the 
alternative proliferation-associated markers including mitotic count, when compared to other 
tumour regions and manual assessments, as well as in the discrimination of good versus poor 
outcome among breast cancer patients (described further in paper III)281.  
 
Figure 9. Virtual dual staining with Visiopharm Integrator System hot spot APP. Aligned CKMNF116 
(a) and Ki67 (b) parallel IHC stained tumour sections. Hot spot (pink circle) identified using the 
heatmap feature (c). High magnification (d-f) of the hot spot area in a-c, respectively. Modified from 
Robertson et al. 2020282, reprinted under a creative common license. 
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The CE IVD hot spot APP has a number of configurable parameters, which enable adaption of 
the hot spot to the user’s objectives. Recently, automated Ki67 assessment using a virtual triple 
staining (pancytokeratin, p63, Ki67) method and the hot spot APP in the VIS showed high 
concordance with the pathologist review and prognostic utility283. Apart from APPs focusing 
on IHC biomarker evaluation, Visiopharm recently launched a CE IVD approved APP for 
detection of lymph node metastasis using an AI approach, and also provides entire software 
systems including Hamamatsu scanners for a digital work flow.  
1.10.3.2 QuPath software 
QuPath is an open source software platform278 for bioimaging designed for digital pathology 
image analysis. The QuPath platform is user friendly and incorporates a broad spectrum of 
annotation and visualisation tools. It is written as a cross-platform java application and apart 
from ready-made algorithms, allows the user to develop custom workflows and add extensions. 
Built-in workflows range from tissue microarray analysis to whole-slide image processing. Cell 
segmentation algorithms allow for object detection across an entire whole-slide image for 
measuring biomarker IHC expression and morphology. This object feature further allows for 
object classification and trainable cell classification (Figure 10). The QuPath software utilises 
machine learning methods such as colour deconvolution, cell segmentation algorithms and 
supervised classifiers275, 284, 285. QuPath has previously demonstrated high reproducibility for 
Ki67 scoring181. In addition, an algorithm for scoring of TILs in malignant melanoma on HE 
sections using QuPath recently demonstrated prognostic potential197. 
 
Figure 10. A QuPath cell classification algorithm for Ki67 scoring in breast cancer. The cell classifier 
correctly identifies different cell types (d-f) in the Ki67 stained tumour slide (a-c). Ki67-positive tumour 
cells in red, Ki67-negative tumour cells in blue, stromal cells in green, immune cells in purple and other 
cells in yellow. Modified from Robertson et al. 2020282, reprinted under a creative common license.  
1.10.4 Machine learning 
The exploding interest and recent breakthroughs in AI may revolutionise the way cancer, 
including breast cancer, is detected and treated in the near future. Machine learning is a subfield 
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of AI that has the ability to learn from data and recognise patterns without human instruction. 
Supervised machine learning models require exposure to a properly labelled training data (e.g. 
images with clinical classification, outcome, annotations) but without the need for specific 
instructions, and can be used for automated pattern recognition and prediction. Unsupervised 
machine learning approaches learn from a data set without labels available. Both methods need 
to be tested on a ground truth test set after the initial training step. 
Deep learning is a recent machine learning approach that has produced ground-breaking results 
in e.g. image classification and speech recognition and uses biologically inspired networks, so 
called neural networks that requires minimal processing on input or output values286. By an 
end-to-end approach to learning it takes raw images (input) and learns a model to produce the 
desired output (Figure 11).  
 
Figure 11. Deep learning versus traditional machine learning. Traditional machine learning with steps 
requiring human expert knowledge to recognise tumour in images (a). Deep learning as an end-to-end 
learning approach that utilises convolutional neural networks (b). Reprinted from Robertson et al. 
2018268, with permission from Elsevier (author’s material). 
Deep learning algorithms are tackling complex pattern recognition tasks in histopathology 
apart from providing computer-aided diagnosis287 and has been applied for detection of tubular 
formation288, nuclear pleomorphism288, 289, tumour grading288-290, as well as for mitosis 
detection287, 291-296. Convolutional neural networks have shown to facilitate classification of 
benign versus malignant lesions297 and invasive tumor detection298, 299 in breast cancer (Figure 
11).  
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Machine learning algorithms are being applied for computer-aided prognostic models based on 
histologic features, gene expression profiling and outcome data combined to distinguish 
patients with more aggressive disease. Although deep learning has demonstrated promising 
results, further studies are needed for validation and to assess their use before models are 
implemented in clinical decision making261, 268. 
1.11 BREAST CANCER TREATMENT 
1.11.1 Surgery 
While surgical removal of the tumour is the established main treatment for early breast cancer, 
surgical approaches have improved considerably over the last decades. There is strong evidence 
from multiple randomised trials with long-term follow up that breast-conserving surgery 
followed by radiotherapy provides survival outcomes equivalent to mastectomy for early breast 
cancer300-302. Recent studies, however, have reported increased breast cancer-specific and 
overall survival after breast-conserving surgery with whole-breast radiotherapy compared to 
mastectomy without radiotherapy303-305. Breast-conserving surgery is recommended as long as 
tumour-free margins can be obtained with an acceptable cosmetic result. Free margins are by 
histopathological examination determined when there is “no tumour in ink”194. For large 
tumours, where primary surgery cannot provide these criteria, the patient may be treated with 
preoperative (neoadjuvant) therapy in order to achieve tumour shrinkage and subsequently 
allow for breast-conserving surgery (see section 1.11.3 for neoadjuvant chemotherapy). Given 
free resection margins, the choice of breast-conserving surgery or mastectomy does not affect 
survival outcomes in patients treated with neoadjuvant chemotherapy (NAC)306. When surgery 
cannot provide margins free of tumour with acceptable cosmetics, in cases of increased 
hereditary risk or patient preference, mastectomy with or without reconstruction is performed. 
For patients with distant metastases at diagnosis (stage IV), treatment is palliative with 
modified individual surgical strategies. 
Axillary lymph node status is one of the most important prognostic factors, additionally 
providing information for therapy decisions307, 308. For clinically node-negative patients, 
axillary staging is performed by sentinel node biopsy. The sentinel node is the first lymph node 
receiving lymphatic drainage from the tumour and is identified with an injected radioactive 
isotope. It is a well-established and reproducible method309-311. Lymph nodes from sentinel 
node biopsies are serial sectioned, stained with HE and examined with immunohistochemistry 
for pan-cytokeratins, in order to detect even single isolated tumour cells. A negative sentinel 
node harbours no or up to 200 isolated tumour cells or single tumour cell clusters within an 
area of £0.2mm85, 96. A positive sentinel node biopsy may contain micrometastasis (N1mic; 
largest tumour cell group >0.2mm and £2.0mm) or macrometastasis (largest cell group 
>2.0mm). Completion of axillary clearance after detection of sentinel node micrometastasis in 
patients treated with breast-conserving surgery and subsequent radiotherapy does not increase 
survival and is not routinely performed312, 313. According to some evidence, the same is true for 
patients with a limited amount of sentinel node macrometastases314. Furthermore, axillary 
radiotherapy may yield equivalent locoregional control and survival outcomes as completion 
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axillary clearance after positive sentinel node biopsy, but results in about half the incidence of 
postoperative lymphedema315. Initiated in Sweden, the prospective randomised SENOMAC 
trial (ClinicalTrials.gov identifier NCT02240472) is currently validating the omission of 
axillary clearance also in patients with 1-2 sentinel nodes with macrometastasis, including even 
the thus far strongly under-represented group of patients undergoing mastectomy316. 
1.11.2 Radiotherapy 
Radiotherapy is the use of ionising radiation for management of malignant disease with the aim 
to eradicate residual microscopic tumour while sparing the surrounding normal tissue. The 
normal tissue can be spared by delivering the irradiation dose in multiple fractions. Ionising 
radiation exposure causes cell cycle arrest, mutation induction, transformation and cell death317. 
The target for radiotherapy is the DNA, and radiation results in DNA double strand breaks, 
single strand breaks and modification318. The radiation sensitivity of cells varies depending on 
which cell cycle phase the cell is in with the mitosis phase being the most radiation sensitive. 
Radiation induces aberrations in the cell and may either be lethal or non-lethal to the cell317.  
Data from large meta-analyses conclude that adjuvant radiotherapy reduces the risk of local 
recurrence and breast cancer-related mortality319. Adjuvant radiotherapy of the breast following 
breast-conserving surgery is standard of care194 and reduces the risk of recurrence with 50% 
after 10 years (rate ratio 0.52) and the risk of breast cancer mortality by a sixth after 15 years 
(rate ratio 0.82)320. Omitting radiotherapy after breast-conserving surgery for early-stage, low-
risk, ER-positive breast cancer is a safe alternative in older patients321. 
For node-positive patients, post-mastectomy locoregional radiotherapy reduces the 10-year 
recurrence risk by three quarters (rate ratio 0.75) and 20-year risk of breast cancer specific 
mortality by a sixth (rate ratio 0.84)322. For node-negative patients, locoregional radiotherapy 
is not generally recommended after mastectomy322; however, tumours >50 mm may benefit 
from adjuvant locoregional radiotherapy. Adjuvant locoregional radiotherapy after 
mastectomy can also be spared patients with only one lymph node metastasis and low grade 
(NHG 1) tumours322.  
1.11.3 Endocrine therapy 
The majority of breast tumours express ER and/or PR and are thus treated with adjuvant 
endocrine therapy for 5-10 years323. For ER-positive breast cancer, several randomized trials 
have demonstrated substantially reduced recurrence and death rates up to 15 years after 5 years 
of adjuvant tamoxifen treatment126. Sensitivity to endocrine therapy is correlated to estrogen 
receptor positivity by IHC126.  
In premenopausal patients who have significant ovarian oestrogenic activity, 5 years of 
tamoxifen is the standard treatment. In premenopausal patients with a high recurrence risk, the 
addition of ovarian suppression through a gonadotropin-releasing hormone agonist to 
tamoxifen or aromatase inhibitors (AIs) improves disease outcomes324, 325. 
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In postmenopausal patients both tamoxifen and AIs are treatment options as monotherapy or 
in sequence326. In a meta-analysis by the Early Breast Cancer Trialists’ Collaborative Group in 
2015, studies comparing 5 years of AIs versus 5 years of tamoxifen showed a significant 
reduction of recurrence with AIs326. Specifically, 5 years of AIs reduced 10-year breast cancer 
related mortality rates by 15% (rate ratio 0.85) and reduced recurrence rates by 30% during the 
first years with different treatment (rate ratio 0.70).  
Both pre- and postmenopausal women with low recurrence risk are recommended tamoxifen 
for 5 years, whereas those with high risk of recurrence (N+ or T3-4) may benefit from 
prolonged endocrine therapy up to 10 years327, 328. The MA.17 trial concluded that 5 years of 
tamoxifen followed by extended AIs therapy improved disease-free survival329, 330. The 
recommendation for postmenopausal patients with high recurrence risk is prolonged therapy 
with AIs. Recent results from the NSABP B-42 trial showed that after the completion of 5 years 
of endocrine treatment, the addition of 5 years of AIs did not increase disease-free or overall 
survival as compared to placebo331. However, the evidence for 5 years of endocrine therapy 
followed by prolonged AIs treatment is hard to evaluate due to limited follow-up, statistical 
power and heterogeneity in randomisation, including fewer side effects among patients with 
prolonged treatment. When considering prolonged endocrine therapy, individual risk 
assessment should be carefully balanced, and multigene assays for risk of recurrence prediction 
may be valuable (see also section 1.7.7)332. Genomic signatures are now included in the 
international recommendations for treatment options for ER-positive early breast cancer with 
limited lymph node involvement (see section 1.7.7)194. 
1.11.3.1 Selective oestrogen receptor modulators 
Selective ER modulators (SERMs), a category of therapeutic agents including tamoxifen, act 
on the oestrogen receptor as competitive partial agonists and/or antagonists depending on target 
tissue. In breast tissue, tamoxifen acts as an oestrogen antagonist, whereas in bone, liver, 
cardiovascular system and uterus it exerts oestrogen agonist activity333. Tamoxifen is a non-
steroidal triphenyl ethylene derivate, which was first approved for breast cancer therapy in 
1977. 
1.11.3.2 Selective oestrogen receptor degraders  
Fulvestrant belongs to the category of selective ER degraders (SERDs). It is a pure oestrogen 
antagonist that bind and destabilises the ER, which is thereby degraded, and exhibits 
antagonistic effects in all tissues333, 334. Fulvestrant is approved for treatment of postmenopausal 
patients with advanced hormone receptor-positive breast cancer with progression following 
routine endocrine therapy335. 
1.11.3.3 Aromatase inhibitors 
Oestrogen biosynthesis starts with cholesterol being converted to progesterone and corticoids, 
then further to androgens (androstenedione or testosterone) and finally to oestrogens (oestrone 
or oestradiol), each step catalysed by different enzymes336. Importantly, the last step is 
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catalysed by the enzyme aromatase. Aromatase inhibitors (AIs) do not block ER but instead 
act by inhibiting the enzyme aromatase. Thus, they reduce the oestrogen production and 
supresses plasma oestradiol, oestrone and oestrone sulphate levels. AIs do not affect ovarian 
oestrogen production, which is the main source of oestrogen in premenopausal women337. In 
postmenopausal women, on the other hand, oestrogen production mostly takes place in 
peripheral tissue such as adipose stroma and muscle336. 
For breast cancer treatment, there are two types of selective AIs with different mechanisms of 
action; irreversible steroidal inhibitors (e.g. exemestane) and nonsteroidal inhibitors (e.g. 
anastrozole and letrozole). The first bind permanently to aromatase and deactivates the enzyme, 
whereas nonsteroidal inhibitors inhibit the synthesis of oestrogen through reversible 
competition336. 
1.11.3.4 Resistance to endocrine therapy 
Approximately 20% of patients with ER-positive primary tumours will later develop 
endocrine-resistant recurrences despite adjuvant therapy338, 339. Endocrine therapy resistance 
includes both de novo and acquired resistance, and the mechanism behind endocrine resistance 
is still elusive and complex. In the majority of tumours, ER expression is retained but the tumor 
cells do nevertheless not respond to endocrine therapy; the tumor has now progressed into a 
hormone refractory state340. This may be driven by ligand-independent ER reactivation, such 
as aberrant activation of receptor tyrosine kinases by mutation or amplification, or activation 
via Ras, which enhances PI3K and MAPK signalling341.  
Acquired mutations in ESR1, encoding ERa, are present in approximately 20% of ER-positive 
recurrences after long-term endocrine therapy342. For ER-positive/HER2-positive tumours, 
endocrine treatment is combined with HER2-targeted therapy. This is a crucial combination, 
since HER2 amplification is known to reduce sensitivity of endocrine agents, mainly by 
activating alternative survival pathways such as PI3K-Akt and MAPK pathways343.  
ER reactivation via MAPK pathways conveys a sensitive target for cyclin-dependent kinase 
(CDK) 4/6 inhibition344, and the addition of CDK4/6 inhibitors (e.g. palbociclib) to anti-
oestrogens in metastatic ER-positive breast cancer has shown promising results. Mutations in 
PIK3CA, encoding PI3Ka, are frequent (up to 40% in ER+/HER2-) in ER-positive tumours 
but without observed differences in rates among primary or resistant recurrences345. In 
PIK3CA-mutated ER-positive advanced breast cancer, however, the addition of the PI3Ka 
inhibitor alpelisib to fulvestrant renders prolonged progression-free survival346.   
Other reported mechanisms comprise epigenetic alterations and tumour microenvironmental 
changes341. Intratumoural heterogeneity of the before-mentioned alterations leading to 
endocrine resistance is a major challenge in the clinical management of metastatic breast 
cancer. Preclinical and clinical approaches including molecular profiling and NGS are 
currently probed for the discovery of novel mechanisms of resistance. Overall, endocrine 
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resistance results in escape of resistant cancer clones, disease progression with need for toxic 
chemotherapy and eventually death in progressive metastatic disease. 
1.11.4 Chemotherapy 
In an early meta-analysis from the Early Breast Cancer Trialists’ Collaborative Group, results 
showed that chemotherapy increased 5-year survival rates and that polychemotherapy was 
more efficient than single-agent chemotherapy347. By 2005, EBCTCG concluded that mortality 
rates could approximately be halved by 6 months of anthracycline-based chemotherapy 
followed by 5 years of tamoxifen338. In an individual patient data meta-analysis, it was further 
demonstrated that combined taxane and anthracycline regimens or high-dose anthracycline 
regimens reduced breast cancer mortality by up to one third348. Today, chemotherapy is 
recommended for HER2-positive, triple-negative, and luminal B-like tumours72. Luminal A-
like tumours seldom require adjuvant chemotherapy, except if tumour burden is high (³T3 or 
³N2). Generally, ER-negative tumours respond best to chemotherapy349. When indications for 
adjuvant chemotherapy are uncertain, gene expression assays can be used. 
For early breast cancer, anthracycline-based (e.g. epirubicin, doxorubicin) and taxane-based 
(e.g. docetaxel or paclitaxel) therapies comprise the standard regimens for chemotherapy, and 
sequential single therapy is generally recommended12, 72. Sequential treatment reduces the risk 
for development of resistance and for cumulative side effects. Anthracyclines combined with 
cyclophosphamide are more effective than cyclophosphamide alone, and are today part of the 
standard therapy (e.g. epirubicin-cyclophosphamide or fluorouracil-epirubicin-
cyclophosphamide). Anthracyclines can lead to severe side effects such as cardiac mortality, 
severe bone marrow suppression, myelodysplastic syndrome and induced leukemia348. The 
combination of taxanes and antracyclinebased regimens (e.g. docetaxel-doxorubicin-
cyclophosphamide) has a higher risk of bone marrow toxicity. Results from multiple trials 
suggest that non-antracycline based regimens (docetaxel/cyclophosphamide) could be an 
alternative in ER-positive, HER2-negative and triple-negative breast cancer245, 350, 351. 
Furthermore, in early triple-negative breast cancer, addition of capecitabin improves disease-
free and overall survival352, 353. Systemic therapies for metastatic breast cancer will not be 
further covered in this thesis. 
1.11.4.1 Neoadjuvant chemotherapy 
Today we see that an increasing number of patients presenting with stage II and III breast 
cancer receive primary systemic therapy, referred to as neoadjuvant therapy. This is also 
evident for triple-negative and HER2-positive breast cancer of any stage194. Neoadjuvant 
therapy allows for real-time evaluation of the tumour response to given therapy and for tailored 
approaches in HER2-positive and triple-negative breast cancer that may improve survival 
outcomes353, 354. Neoadjuvant chemotherapy (NAC) compared with adjuvant chemotherapy 
does, however, not improve distant recurrence-free or overall survival, but is associated with 
increased risk of local recurrence355. Highest benefit of neoadjuvant chemotherapy is seen for 
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HER2-positive and triple-negative tumours. pCR in the surgical specimen after neoadjuvant 
therapy has prognostic value and is associated with improved survival99.  
1.11.5 HER2-targeted therapy 
The advances in HER2-targeted therapies have dramatically improved the prognosis for HER2-
positive disease and nowadays patients with metastatic disease treated with trastuzumab have 
been shown to have better prognosis than those with HER2-negative disease158. In 1998 the 
humanised anti-HER2 monoclonal antibody trastuzumab received approved by the Food and 
Drug Administration and was the first agent targeting HER2 in breast cancer356, 357. Shortly 
thereafter studies demonstrated prolonged survival in metastatic breast cancer treated with 
trastuzumab and chemotherapy and later with single-agent therapy in metastatic HER2-positive 
breast cancer156, 358. Since then several studies with long-term follow up have demonstrated 
improved overall survival and disease-free survival in early HER2-positive breast cancer359. 
The HERA trial showed that prolonged trastuzumab treatment (two years) did not improve 
survival outcome compared to one year360. Trastuzumab is currently the therapy of choice both 
in the adjuvant and neoadjuvant setting for early HER2-positive breast cancer72, 194, 361. 
Trastuzumab is generally recommended together with taxane-based chemotherapy but 
anthracyclines are to be avoided due to heart toxicity362.  
1.11.5.1 Monoclonal anti-HER2 antibodies 
Trastuzumab binds the extracellular juxtamembrane domain IV of HER2, which inhibits HER2 
signalling through several mechanisms including prevention of homodimerisation, increased 
destruction of the receptor and activation of antibody-dependent cell-mediated cytotoxicity363. 
This is, however, not the only way to inhibit HER2-signalling and a handful of HER2-targeted 
agents have received approval for HER2-positive breast cancer. These advances have led to 
several novel agents currently in clinical trial investigations150.  
The monoclonal antibody pertuzumab binds to a different domain of HER2 compared to 
trastuzumab and prevents heterodimerisation of HER2 with EGFR (HER1) and especially 
HER3. Thus, preventing activation of PI3K pathway signalling through HER2-HER3 
dimers157. Clinical benefit of pertuzumab added to trastuzumab was shown in HER2-positive 
metastatic breast cancer after progression on trastuzumab364. In the adjuvant setting, dual HER2 
blockade with pertuzumab combined with trastuzumab and chemotherapy was shown to 
improve disease-free survival, especially among node-positive patients but long-term results 
are pending365. This dual HER2-targeted therapy also showed to increase pCR rates when 
administered together with neoadjuvant chemotherapy366, 367. The benefit in relation to costs of 
adjuvant pertuzumab is currently limited to selected high-risk HER2-positive patients.  
1.11.5.2 Small-molecule tyrosine kinase inhibitors 
The small-molecule tyrosine kinase inhibitors lapatinib and neratinib are clinically approved 
for HER2-positive breast cancer150. Addition of the oral HER1 and HER2 tyrosine kinase 
inhibitor lapatinib, demonstrated increased outcomes in metastatic breast cancer and increased 
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pCR when added to trastuzumab in the neoadjuvant setting368, 369. However, in the adjuvant 
setting, lapatinib failed to improve disease-free survival and added toxicity compared to 
trastuzumab alone370. Neratinib is an irreversible pan-HER tyrosine kinase inhibitor targeting 
HER1, HER2 and HER4, and is orally administrated371. Recent data suggests that prolonged 
anti-HER2 therapy with neratinib, after one year of adjuvant trastuzumab lowers the risk of 
recurrence372. 
1.11.5.3 Antibody-drug conjugates 
The antibody-drug conjugate trastuzumab emtansine combines trastuzumab with a cytotoxic 
maytansine derivate and microtubule inhibitor373. Thus, this drug inhibits HER2 and delivers 
cytotoxic effects intracellularly. Trastuzumab emtansine was clinically approved for HER2-
positive pre-treated metastatic breast cancer374, 375, and is also recommended for HER2-positive 
residual tumour after neoadjuvant treatment194, 354. Several antibody-drug conjugates are 
investigated in clinical trials150. 
1.11.5.4 Risk stratification for HER2-positive breast cancer 
Biomarker analysis in routine cancer diagnosis requires considerable resources and is 
hampered by insufficient specificity, which is also evident for HER2 analysis. There are 
currently no molecular assays for risk stratification of HER2-positive breast cancer. Thus, 
therapy decisions are based on HER2 testing along with ER status and disease stage. Several 
studies have demonstrated the relationship of the HER2 receptor with hormone dependency 
and the association between HER2 amplification and hormone receptor negativity376. This is 
supported by the occurrence of HER2-positive tumours not responding to endocrine therapy377. 
Deeper knowledge of the HER2 expression patterns and their correlation to outcome after 
adjuvant anti-HER2 therapy could be a key to selecting a personalised HER2-targeting therapy. 
Alternative methods for HER2 assessment have potential to improve stratification of patients 
into therapy-responsive subgroups. A clinical important difficulty is distinguishing patients 
who will derive substantial benefit from escalating therapy from those who instead would do 
as well with de-escalating therapy.  
1.11.5.5 Resistance mechanisms to HER2-targeted therapy 
Despite the established therapy predictive role of HER2 testing methods they lack accuracy to 
distinguish therapy-resistant tumours. Unfortunately, some HER2-positive tumours progress 
on HER2-targeted therapy. Several mechanisms of intrinsic and acquired resistance to HER2-
targeted therapies have been described150. Incomplete inhibition of the HER family, could 
potentially be overcome by combinations of targeted therapies. The presence or acquisition of 
genetic, epigenetic or post-translational of HER2 can thus impair effective inhibition. The 
understanding of and the clinical importance of e.g. ERBB2 mutations at progression after prior 
HER2-targeted therapy is continuously evolving. In the case of effective inhibition of HER2, 
three main mechanisms of resistance have been described: dysregulation of downstream 
signalling pathways (e.g. via PIK3CA mutations), bidirectional crosstalk with ER and 
upregulation of escape pathways150. In recent years, it has been discovered that the immune 
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system may be involved in the response to anti-HER2 therapies190, 378, since immune infiltration 
is associated with better prognosis in HER2-positive breast cancer190, 196, 379.  
1.11.6 Emerging targeted therapies 
The emerging spectrum of targeted therapies in clinical trials for breast cancer treatment cannot 
be covered in this thesis, but they are generally investigated in the metastatic setting. As 
mentioned in section 1.11.3, several agents targeting the PI3K-Akt-mTOR pathway have been 
developed to enhance the effect of endocrine therapy in ER-positive breast cancer341. The 
specific PI3Ka inhibitor alpelisib, was recently approved for PIK3CA-mutated ER-positive 
advanced breast cancer in combination with fulvestrant346. There are also several mTOR 
inhibitors, such as everolimus, which is approved for metastatic breast cancer in combination 
with AI regardless of PIK3CA status380. Furthermore, several inhibitors targeting Akt are under 
investigation341. 
CDKs are central player in cell-cycle regulation, and CDK4/6 inhibition demonstrated 
reversing endocrine resistance in advanced ER-positive breast cancer381. The most studied 
CDK4/6 inhibitor is palbociclib, which demonstrated improved outcome for both endocrine 
treatment naïve and pre-treated patients with advanced disease382, 383. There is however, no 
conclusive evidence for appropriate biomarkers for the current CDK4/6 inhibitors384. 
The emerging field of immunotherapies for cancer treatment has gained large interest in recent 
years. Immune checkpoint blockade using monoclonal antibodies against CTLA-4, PD-1 and 
PD-L1 have shown promising results across several tumour types385-389. In breast cancer, check 
point inhibitors targeting PDL-1/PD-1, such as atezolizumab, have been approved for 
metastatic triple-negative breast cancer204, 205 and is further discussed in section 1.6.6.  
The use of angiogenesis inhibiting drugs in breast cancer is not conclusive. In selected patients 
with advanced breast cancer the monoclonal antibody bevacizumab targeting VEGF, could 
potentially be added to chemotherapy390. Furthermore, for BRCA-mutated advanced breast 
cancer, Poly (adenosine diphosphate-ribose) polymerase inhibitors show promise391, 392. 
Further therapies available for advanced breast cancer will however, not be covered in this 
thesis. 
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2 AIMS OF THE THESIS 
The overall objective was to improving the accuracy for assessment and prognostic value of 
prognostic and predictive biomarkers in routine breast pathology; to this end, we compared 
standard methods with the prognostic potential of digital image analysis techniques and gene 
expression assays. 
Specific aims: 
Paper I 
• To investigate the concordance of biomarker assessment, surrogate subtypes and 
molecular subtypes on preoperative fine-needle aspiration cytology versus 
corresponding resected breast tumours. 
Paper II 
• To estimate the value of re-testing biomarkers from core needle biopsies in 
subsequently surgically resected breast tumours, with emphasise on HER2 and 
surrogate subtype concordance, in the adjuvant and neoadjuvant setting. 
Paper III 
• To compare the clinical relevance of mitotic counts, Ki67 and PHH3 in early breast 
cancer, and clarify which proliferation marker is better in terms of prognostic potential, 
sensitivity and specificity fin distinguishing molecular subtypes luminal B and A, and 
transcriptomic grade. 
• To investigate differences in scoring proliferative activity in hot spots, invasive tumour 
margins and across the entire tumour, in relation to outcome. 
Paper IV 
• To investigate different configurable parameters for defining a digital hot spot for Ki67 
scoring with regards to prognostic potential. 
• To compare the prognostic potential for Ki67 hot spot scoring and global scoring using 
different digital image analysis platforms in ER+/HER2- breast tumors. 
Paper V 
• To investigate the prognostic significance of HER2 copy numbers, HER2/CEP17 ratio, 
and ERBB2 mRNA gene expression levels in a HER2-positive breast cancer cohort 
treated with HER2-targeted therapy.
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3 MATERIALS AND METHODS 
3.1 PATIENT COHORTS 
3.1.1 The immunocytochemistry versus immunohistochemistry cohort 
In paper I we designed a retrospective cohort consisting of patients with primary breast cancer 
diagnosed by FNAC during 2005 and 2006 at the Karolinska University Laboratory or Capio 
St Göran’s Hospital, Stockholm, Sweden. A total of 301 tumours with biomarker evaluations 
both from cytology and the corresponding surgical specimen were included. Exclusion criteria 
were as follows: neoadjuvant therapy, previous breast cancer within the past 5 years and 
missing Ki67 value. Clinicopathological data, including biomarker status, were retrieved from 
the laboratory information system and medical records, with end of follow-up in July 2016. 
Overall and breast cancer-specific survival were the measured outcomes. The cohort had a 
median follow-up time of 10.3 years. 
3.1.2 The core biopsy versus surgical specimen cohort  
In paper II, a retrospective study cohort was designed, consisting of 716 patients with primary 
breast cancer diagnosed at the Karolinska University Laboratory during 2016 and 2017, and 
available biomarker evaluations both on CNBs and paired surgical specimens. Two cohorts 
were created: a primary surgery cohort (n = 526) without NAC, and a NAC cohort (n = 190) 
with NAC based on biomarkers from CNBs. Patients with pCR after NAC and those with 
neoadjuvant endocrine therapy alone were excluded. Clinicopathological data were retrieved 
from routine pathology reports and medical records, with end of follow-up in March 2018. 
3.1.3 The Clinseq cohort 
The Clinseq study cohort of primary breast cancers comprises patients diagnosed in 2002-2010 
at the Karolinska University Hospital and in 2012 at the Stockholm South General Hospital, 
respectively and included in the retrospective Libro1 and prospective KARMA tissue banks. 
The Clinseq study cohort contained 307 patients with fresh-frozen tumour tissue and germline 
DNA from blood, apart from routine FFPE tumour tissue. The study cohort has previously been 
described in detail258. Apart from PAM50 subtype classification (described in section 3.5), each 
tumour had been assigned a ‘transcriptomic grade’ based on RNA sequencing data393. No new 
gene expression data was performed in the studies of this thesis. 
In paper I, we identified 84 tumours with corresponding preoperative cytology and ICC-
assessed biomarkers from the Clinseq cohort that were used for biomarker and PAM50 subtype 
comparisons. ‘Transcriptomic grade’ was used for comparisons in paper III. Here, whole 
tumour sections of 204 tumours from 196 patients were stained for Ki67, PHH3 and 
CKMNF116, and digitised at x20 with a NanoZoomer 2.0 HT (Hamamatsu Photonics K.K., 
Japan) for DIA. All tumours had available PAM50 subtype and clinicopathological data. Out 
of these tumours, 139 ER-positive/HER2-negatve tumours were included in paper IV for DIA 
of Ki67 scoring methods. 
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3.1.4 The Stockholm cohort 
The population-based so called ‘Stockholm cohort’ consists of 524 patients with primary breast 
cancer who underwent surgery at the Karolinska University Hospital during 1994 to 1996. 
Patients were identified in and clinicopathological data was retrieved from the National Breast 
Cancer Register and medical records. This cohort included 5- and 10-year overall survival data. 
The study cohort has been described and published previously280, 394, 395. After exclusions (only 
FFPE tissue, insufficient material for RNA expression arrays, neoadjuvant therapy, stage IV), 
fresh-frozen tumour material for RNA expression profiling was available for 159 tumours. 
Molecular subtype classification had been performed (see section 3.5) and histological grade 
re-evaluated by an experienced pathologist.  
In paper III, whole tumour sections of 90 tumours from 84 patients were stained for Ki67, 
PHH3 and CKMNF116, and digitised at x20 with a NanoZoomer 2.0 HT  for DIA. All tumours 
had available molecular subtype and clinicopathological data. 
3.1.5 The Stockholm HER2 cohort 
For paper V, we designed a study cohort comprising patients with HER2-positive primary 
breast cancer who were treated with HER2-targeted therapy (trastuzumab). This cohort is 
referred to as the ‘Stockholm HER2 cohort’ and consists of 591 patients diagnosed at the 
Karolinska University Laboratory, Stockholm, Sweden, 2006-2014. Only patients with 
available detailed HER2 status from either CNB or surgical specimen were included. 
Clinicopathological data were retrieved from laboratory information system and medical 
records, with follow-up until June, 2020. The following exclusion criteria were applied: stage 
IV disease, previous ipsilateral breast cancer, bilateral breast cancer, lack of follow-up data, 
HER2 negativity, lack of HER2-targeted therapy. Archived FFPE tumour tissue blocks were 
retrieved from 460 cases, from which parallel sections were stained for HE, HER2 IHC and 
HER2 ISH. All stained sections were scanned at x40 with a NanoZoomer XR (Hamamatsu 
Photonics K.K., Japan) and digitized for pathological assessment by experienced pathologists. 
Additional macro-dissected tumour material from parallel sections was used for RNA 
extraction protocols including STRAT4 gene expression analysis (described in section 3.6).  
3.2 TUMOUR TISSUE SAMPLES 
Tumour tissue from core biopsies or surgical resections (described in section 1.4.3 and 1.4.4) 
were fixed using 4% formaldehyde upon arrival to the pathology department. The entire biopsy 
or cut tumour pieces was paraffin-embedded into tissue blocks after dehydration. The tissue 
block is sectioned in 3-4 µm thin sections and mounted on glass slides. The whole tumour 
tissue sections were stained with HE and additional immunohistochemical stains or ISH as 
described below. All clinical FFPE tissue blocks and glass slides were stored in archives as 
valuable resource that enables not only diagnostic review but also tissue for research use. From 
surgical resections, small samples of fresh tumour tissue were obtained and snap-frozen for 
storage in the medical biobanks prior to fixation. This enables important opportunities for 
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studies of preserved DNA and RNA for high quality sequencing, both for clinical purposes and 
research.  
In contrast, fine needle aspiration-based cytological assessments from breast tumours were 
performed by smear cytological evaluations and additional air-dried smears for 
immunocytochemical analysis of biomarkers (ER, PR and Ki67). As described in section 1.4.2, 
FNAC is an established method for breast cancer diagnosis at the Karolinska University 
Hospital. Liquid-based cytology techniques are mainly used for cervical cancer screening, but 
could be adapted for FNAC396. Cell block preparation is a technique where cytological material 
is processed, sectioned and stained as a histological sample, and thus allows for IHC staining 
and ISH397.  
3.3 IMMUNOCYTOCHEMISTRY AND IMMUNOHISTOCHEMISTRY 
Immunohistochemistry (IHC) is a technique for detection of antigens (proteins) in tissue by 
specific antibodies, and immunocytochemistry (ICC) is the same principal procedure used for 
cytological material398. IHC visualises the protein of interest in the tissue and provides 
information on its location in specific cellular compartments, such as the nucleus, the 
cytoplasm or the cell membrane. In the early 1990’s heat-induced epitope retrieval methods 
revolutionised the practice of pathology by enhancing retrieval in FFPE tissue and revealing a 
large variety of proteins399. In today’s pathology departments, IHC staining has advanced from 
previously being a complex manual process to a fully automated process. Automated staining 
platforms include steps as slide labelling, baking, de-paraffinisation, antigen retrieval, staining, 
cover-slipping, and in some cases even digital image analysis. 
Rabbit and mouse are the most common hosts for antibody production. The host is injected 
with the antigen of interest whereby polyclonal antibodies are produced by several different 
plasma cell lineages as a response and antiserum containing polyclonal antibodies is obtained. 
In contrast, monoclonal antibodies are produced using in vitro tissue culture techniques; 
immune cell tissue (e.g. spleen) is removed from the host immunised with the specific antigen 
and immortalised cells are cultured to continue producing monoclonal antibodies. Importantly, 
polyclonal antibodies bind to multiple epitopes on a specific protein leading to high sensitivity 
but less specificity, while a monoclonal antibody only binds to one specific epitope, rendering 
high specificity. An epitope can consist of only a few amino acids. In the staining procedure, 
secondary antibodies that bind to the primary antibody are used to visualise the protein 
expression by either a chromogen, e.g. diaminobenzidine that is converted to a brown product 
by horseradish peroxidase tagged to the secondary antibody, or in the case of 
immunofluorescence a fluorophore.  
Throughout the papers presented within this thesis, IHC staining was performed using the 
following antibodies: monoclonal rabbit anti-Ki67 (Ventana Medical Systems, USA: clone 30-
9), anti-PHH3 (Biocare Medical, USA: clone BC37) and anti-HER-2/neu (Ventana Medical 
Systems, USA: clone 4B5) antibodies, and the mouse monoclonal anti-cytokeratin (Agilent 
Dako, USA: clone MNF116) antibody. The retrospective biomarker evaluations retrieved from 
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pathology reports had all been ICC and IHC stained using current routine protocols 
(monoclonal rabbit anti-ER (clone SP1), anti-PR (clone 1E2), anti-Ki67 (clone 30-9) and anti-
HER2/neu (clone 4B5) antibodies or mouse monoclonal anti-Ki67 (clone MIB-1; for ICC) 
antibody) at the accredited department of Pathology/Cytology, Karolinska University 
Laboratory, Stockholm, Sweden. The ICC and IHC protocols used in the papers included in 
this thesis are described in the ‘materials and methods’ sections of each paper. 
3.4 IN SITU HYBRIDISATION 
In situ hybridisation (ISH) is a technique widely used to visualise gene amplifications, 
deletions, translocations and chromosomal copy number alterations in cells. ISH testing uses a 
labelled probe that recognises and hybridises to the target gene, and thereby enumerates the 
targeted gene copy numbers within the cells164. The DNA probe can be coupled to a fluorescent, 
chromogenic or silver detection system, or combination thereof for detection. Fluorescent ISH 
required a fluorescence microscope for evaluation, whereas an advantage of chromogenic and 
silver ISH is that they are evaluated in a brightfield microscope.  
Fluorescent ISH signals fade over time and for paper V, re-testing of HER2 was performed by 
IHC and silver ISH on archived FFPE tumours. The HER2 dual-probe ISH staining 
VENTANA HER2 Dual ISH DNA Probe Cocktail assay (Roche Diagnostics, Rotkreutz, 
Switzerland) together with VENTANA Silver ISH DNP Detection kit and VENTANA Red 
ISH DIG detection kit was utilized according to the manufacturer’s instructions (BenchMark 
ULTRA IHC/ISH Staining Module, Ventana Medical Systems, Arizona, USA). HER2 gene 
status was determined by brightfield light microscopy and on digitalised images. Details on 
HER2 ISH evaluations are described in detail in section 1.6.2. 
3.5 PAM50 - GENE EXPRESSION PROFILING 
Originating from microarray gene expression data Perou et al. identified the four breast cancer 
intrinsic subtypes with clinical implications58, and later Parker et al. developed a 50-gene single 
sample predictor classifier for subtype assignment214. As described in section 1.7.7, 
NanoString’s Prosigna test was approved. Research-based PAM50 subtyping is widely used. 
The PAM50 classifier makes calls based on the 50-gene centroid correlation distance to 
subtype-specific centroids214.  
3.5.1 RNA sequencing 
In the papers within this thesis (paper I, III-IV), RNA extraction (Qiagen AllPrep kit, 
Germany) from snap-frozen tumour tissue in the ‘Clinseq cohort’ had previously been 
performed and used for PAM50 subtype classification. In brief, stranded RNAseq libraries 
were constructed (TruSeq Stranded Total RNA Library prep kit, Illumina, USA). Gene-level 
expression estimates were calculated (HTSeq count version 0.6.1)400 and normalised (TMM 
method401 in edgeR package402) using Python and R frameworks for analysis of high-
throughput sequencing data. Unaligned RNAseq data from the Cancer Genome Atlas (TCGA) 
breast cancer data set212 was run in parallel as reference. Molecular subtypes (luminal A, 
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luminal B, HER2-enriched and basal-like) had been assigned using the Nearest Shrunken 
Centroid classifier and the PAM50 gene set214 using parameters from the TCGA dataset258. The 
‘Clinseq’’ and TCGA datasets were pre-processed using the same bioinformatic pipeline to 
reduce potential batch differences. 
3.5.2 Microarray gene expression 
In paper III, molecular subtype classification of the ‘Stockholm cohort’ had been performed 
using DNA microarray profiling394, 395. In brief, RNA was extracted (RNeasy mini protocol, 
Qiagen, Germany) from snap-frozen tumour tissue. Microarray profiling was performed using 
protocols of Affymetrix HG-U133AB gene-chip arrays (Affymetrix, USA) for preparation of 
in vitro transcription products and oligonucleotide array hybridisation, and scanning. Raw 
expression data were normalised using a global mean method403. For microarray data analysis, 
genes were selected based on the ‘intrinsic’ gene list described by Sorlie et al217. Gene 
expression data from Affymetrix chips was matched with the publicly available reference 
dataset used by Sorlie and colleagues. Genes were median-centred and molecular subtypes 
(basal-like, ERBB2, luminal A, luminal B and normal-like) were defined by a hierarchical 
clustering of the reference dataset394. 
3.6 STRAT4 GENE EXPRESSION ASSAY 
STRAT4 is a closed-system real-time quantitative RT-PCR (RT-qPCR) assay (XPERT® Breast 
Cancer STRAT4 Assay, Cepheid, Sunnyvale, USA). It is a CE-IVD RT-qPCR test that 
involves primers and probes to measure ERBB2 (HER2), ESR1, PGR and MKi67 transcripts 
together with an endogenous control gene, Cytoplasmic FMR1-Interacting Protein 1 
(CYFIP1), and was used in paper V. Tumour tissue lysate aliquots were added to the 
GeneXpert cartridge containing the assay reagents, sample-preparation and STRAT4 RT-
qPCR assay, which utilises a specific computer system and the GeneXpert Instrument system 
(Cepheid, Sunnyvale, USA). This semi-automated targeted gene expression assay provided 
transcript results within 2.5 h with limited manual handling. 
ESR1, PGR, ERBB2 and MKi67 target gene cycle threshold (Ct) measurements by the system 
are individually normalised against the Ct of the reference gene, CYFIP1, resulting in delta Ct 
values (dCt). The target mRNA dCt measurements were classified as positive or negative based 
on pre-defined dCt detection cut-offs for each target mRNA based on previous studies404, 405.  
3.7 DIGITAL IMAGE ANALYSIS  
3.7.1 Visiopharm Integrator System 
The Visiopharm Integrator System (VIS) provided by Visiopharm A/S (Hoersholm, Denmark) 
was used in paper III and IV, in academic collaborations. See section 1.10.3.1 for general 
descriptions of the VIS software. In paper III and IV, DIA methods were applied for 
investigation of IHC Ki67 and PHH3 scoring. The VIS virtual double staining method operates 
by virtually aligning a pan-cytokeratin section with the biomarker section (e.g. Ki67 or PHH3), 
and thereby excludes non-epithelial cells from analysis. However, this method cannot 
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distinguish in situ from invasive lesions, and manual review to eliminate regions of DCIS by 
annotations from a pathologist is required. The different steps in image analysis in VIS is run 
by specific APPs (PCK APP, Ki67 APP, VDS APP, hot spot APP etc) designed for breast 
cancer. The details for annotations of invasive edges and average scoring across full sections 
are described in ‘material and methods’ section of paper III. The details of all configurable 
hot spot APP parameters are described in the ‘materials and methods’ section in paper IV. 
3.7.2 QuPath  
QuPath is an open source bioimage analysis software designed for image analysis of whole-
slide images in pathology278 and is described in section 1.10.3.2. A key feature is the 
hierarchical object-based data model, where the object is a structure or region in the image that 
is detected or annotated. This system allows for classification of objects and maintain 
relationships between objects. In paper IV, QuPath was used for global scoring of Ki67. 
Algorithms for Ki67 scoring were based on a cell classifier identifying tumour cells from 
stromal cells, immune cells and others using machine learning methods. The Ki67 score was 
calculated as the percentage of all Ki67-stained tumour cells out of all tumour cells on the 
whole-slide image. Larger areas of DCIS were eliminated from the analysis by manual 
annotations by a pathologist. Further details are described in the ‘materials and methods’ 
section in paper IV. 
3.8 STATISTICS 
The statistical methods used in this thesis is described in “materials and methods” of each paper 
(paper I-V). Only the main statistical methods are summarised here. All statistical tests were 
two-sided and significance considered at a p<0.05 level.  
Normal distribution was tested with Kolmogorov-Smirnov test of normality. Comparison of 
proportions with categorical outcome was performed with the Chi-squared test and Fisher’s 
exact test. The Mann-Whitney U test was applied as non-parametric test for independent 
samples with continuous variables. 
Non-parametric tests for two dependent samples were as follows: McNemar’s test or Fisher’s 
exact test for paired samples with two categories and the Marginal Homogeneity test for paired 
samples with more than two categories. Related-samples Wilcoxon signed rank test was 
applied to continuous outcome data.  
Pearson’s correlations and Spearman’s rank order coefficients were calculated for continuous 
variables. Cohen’s k statistics were evaluated for the level of agreement between categories. 
The Landis and Loch 1977 agreement categories for k-values were applied as follows: 0.21-
0.4 as fair, 0.41-0.6 as moderate, 0.61-0.8 as substantial and 0.81-1 as almost perfect agreement. 
The agreement between scoring methods in paper IV was assessed in a Bland-Altman plot. 
In paper II we defined ‘numbers needed to re-classify’ (NNRC) as 1/risk of re-classification, 
in analogy with ‘numbers needed to treat’. Receiver operating characteristics (ROC) and area 
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under the curve (AUC) methods were performed for determining new cut-offs, with equal 
emphasis on sensitivity and specificity (paper I and III). The intraclass correlation coefficient 
was used to test reproducibility in paper IV using log-transformed Ki67 values. 
The Kaplan-Meier survival estimates were calculated for overall survival (OS), breast cancer-
specific survival (BCSS) and recurrence-free survival (RFS). Cox regression likelihood ratio 
(LR) c2 and change in LR (LR - Dc2) were used to test individual and relative prognostic values 
(paper I). The Cox proportional hazards regressions models for univariate and multivariate 
analysis was used to estimate the hazard ratios (HR) for recurrence or death.   
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4 RESULTS AND DISCUSSION 
4.1 PAPER I 
 
Prognostic value of Ki67 analysed by cytology or histology in primary breast cancer 
Accurate biomarker assessment is crucial for breast cancer management and therapy decisions. 
International guideline recommendations state that ER, PR, HER2 and Ki67 should be analysed 
from preoperative biopsies or surgical resections72-74. Since tumour progression may affect 
biomarker expression, re-analysis from metastatic sites is important, and may in some cases 
only be accessible for fine-needle aspiration. However, biomarkers, especially Ki67 are prone 
to both interobserver and intraobserver variability114, 115. The accuracy and concordance of 
biomarker evaluations across different tissue sample types has clinical implications. The IHC-
based biomarkers are used to classify tumours into surrogate subtypes, which act as clinical 
surrogates for molecular subtyping. In the local clinical setting at the Karolinska University 
Hospital, preoperative ICC biomarker assessments were performed even though re-testing by 
IHC followed on all invasive breast tumours. This dual biomarker analysis provided a unique 
possibility to investigate the diagnostic efficacy and prognostic value of the two methods.  
In paper I, we investigated the concordance of original biomarker evaluations from FNAC and 
consecutive surgical specimens in two combined cohorts comprising 385 tumours. Overall, the 
median Ki67 was higher in surgical resections compared with aspiration cytology. The 
concordance rate for Ki67 was 66% (k 0.35) for paired samples, meaning that 34% of the 
tumours changed from low to high Ki67 score or vice versa between the two methods. High 
concordance was observed for ER (97%, k 0.88). 
In addition, we used surrogate subtype classifications and PAM50 subtypes to investigate the 
concordance between both methods. The concordance rate for surrogate subtypes based on ICC 
versus IHC reached 65%. Almost 50% of the tumours classified as luminal A-like on cytology 
were reclassified to luminal B-like after surgical resections. In the subset of tumours with 
available PAM50 subtype, cytology-based surrogate subtypes showed a 60% concordance rate 
(k 0.23) and similarly, histology-based surrogate subtype classification had a 64% concordance 
rate (k 0.31). Thus, neither of the two methods was excellent nor superior for agreement with 
gene expression-based subtypes. 
Kaplan-Meier survival curves demonstrated that high Ki67 using IHC from resections was 
significantly associated with worse outcome in terms of an increased HR for overall death 
compared with low Ki67 tumours. No significant difference in overall survival between low 
and high Ki67 groups from cytology was observed. The results were similar when adjusted 
cut-offs were used. The individual prognostic values of ICC and IHC Ki67 scores were tested 
and showed that IHC but not ICC contributed with significant prognostic information.  
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In summary, we found a considerable difference in prognostic value of Ki67 scoring depending 
on diagnostic method. We demonstrate the prognostic significance of IHC assessment of Ki67 
from surgical specimens compared to ICC from FNAC in terms of predicting lymph node 
metastasis and survival outcome. Regarding subtype classification, both ICC and IHC-based 
methods are suboptimal in predicting true molecular subtypes. 
4.2 PAPER II 
Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically 
relevant 
After paper I, the next step was to investigate the concordance of the four biomarkers and 
surrogate subtypes from CNBs and paired surgical specimens. The accuracy of biomarker 
evaluation in breast cancer is not only paramount in the adjuvant setting but even more so in 
the neoadjuvant setting, where treatment decisions are based on preoperative CNB results. 
Among patients with ER-positive/HER2-negative tumours, high Ki67 aids to distinguish the 
more aggressive luminal B-like tumours from luminal A-like, and is of clinical importance for 
decision regarding the benefit of neoadjuvant or adjuvant chemotherapy. In paper II, the 
agreement between preoperative CNB and paired tumour specimens regarding biomarker 
status and surrogate subtypes was evaluated in 526 adjuvantly and 190 neoadjuvantly treated 
patients. 
In the adjuvantly treated primary surgery cohort, there were significant differences in ER, PR 
and Ki67 scores between CNB and paired resection. ER status had an almost perfect agreement 
between samples (99% concordance rate) and PR status a substantial agreement (89% 
concordance rate). The concordance rate for Ki67 was 79%, thus moderate agreement (k 0.53), 
and only five tumours needed to be assessed on CNB before one was re-classified on resection 
(NNRC=5). Accordingly, ER status had the highest NNRC, meaning that 73 tumours needed 
to be evaluated on CNB for one to be re-classified on resection specimen. In the NAC cohort, 
similar results were observed for ER and PR. As expected, Ki67 was decreased in surgical 
specimens after NAC, and thus only slight agreement was observed. 
The concordance for HER2 IHC was 75% with moderate agreement (k 0.46), which was 
further improved when IHC was combined with ISH for HER2 status. NNRC for HER2 status 
was 28. However, 3.6% of the cases had discordant HER2 status. In the NAC cohort, HER2 
status had a 94% concordance rate with substantial agreement. 
To further investigate the clinical application of these findings, IHC-based surrogate subtypes 
according to the 2013 St Gallen consensus77 and current Swedish guidelines109 were compared 
between CNB and surgical resections. The concordance rates applying these to subtype 
classifications were 78% (k 0.63) and 73% (k 0.59), respectively. With both classifications, 
38% luminal A-like tumours on CNB were re-classified as luminal B-like on the surgical 
resection.  
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In summary, we demonstrate that the agreement of Ki67 and HER2 between CNBs and surgical 
specimens is insufficient in primary tumours among patients with or without NAC. In addition, 
the limited agreement of surrogate subtype classifications indicates the clinical importance of 
re-testing biomarkers on surgical specimens. 
4.3 PAPER III 
Digital image analysis of Ki67 in hot spots is superior to both manual Ki67 and mitotic 
counts in breast cancer 
Evaluation of tumor proliferation, one of the hallmarks of cancer, is currently included in the 
routine biomarker assessment for breast tumours by manual counting of mitosis and IHC 
scoring of Ki67 protein expression. Despite the established prognostic and predictive value of 
Ki67 in early breast cancer172, it remains one of the most criticised and controversial 
biomarkers. For patients with luminal A-like and luminal B-like tumours, Ki67 is an important 
surrogate marker to distinguish between patients who may benefit from adjuvant chemotherapy 
(luminal B-like) and those who will instead be over-treated while potentially suffering adverse 
effects (luminal A-like). The international recommendations for the use of Ki67 to guide 
clinical decisions regarding chemotherapy are conflicting due to the lack of reproducibility and 
standardisation. Large efforts have been made to improve the intra- and interlaboratory 
variability of manual Ki67 assessment. Over the past years, the recommendations for Ki67 cut-
offs have changed repeatedly, and there is still no established international consensus on which 
cut-off to adopt for dichotomising low and high proliferation. Apart from cut-offs, neither has 
a standardised method for scoring Ki67 been established. To overcome parts of the 
reproducibility concerns, DIA methods have been suggested to improve reproducibility and 
provide methods for standardisation181-183. 
In paper III, we investigated the clinical relevance of mitoses, Ki67 and PHH3 in the combined 
Clinseq and Stockholm cohorts comprising 294 primary breast tumours. In addition, we sought 
to identify the best tumour region for assessment of proliferation (hot spots, invasive front and 
across entire tumour section) in relation to outcome. All DIA was performed using the VIS 
Apps. 
Among luminal A and B tumours, AUC derived from ROC analysis for the tested methods 
showed that regardless of the tumour region DIA of Ki67 outperformed the other markers 
(mitotic rate, PHH3 mitotic rate, manual Ki67, and DIA PHH3) in sensitivity and specificity 
for luminal B subtype.  
Cut-offs for each marker were selected based on AUC-ROC scores in relation to OS and RFS. 
However, no meaningful cut-off could be found for DIA of PHH3. Based on these cut-offs, 
Cox regression HRs for all-cause mortality were significantly increased for high versus low 
proliferation groups, using DIA of Ki67 in hot spots (HR 2.97) and full tumour section (HR 
2.19) as well as PHH3 counts/10 high-power-fields (HR 2.19). Kaplan-Meier curves also 
showed that DIA of Ki67 regardless of region was superior to mitotic counts, manual Ki67 and 
PHH3 in separating patients into poor versus relatively good overall survival groups. 
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Histological grading based on automated Ki67 scores instead of mitoses increased the 
differences in overall survival between grade 1 and 3, and added significant prognostic 
information. 
In summary, this study showed that DIA scoring of Ki67 in hot spots outperformed the 
alternative markers, most importantly in discriminating prognostic groups. Histological 
grading based on automated Ki67 scores showed increased prognostic potential. Altogether 
these findings suggest that when using the VIS virtual double staining method, DIA of Ki67 in 
hot spots should be the marker of choice for assessment of proliferative activity in breast 
cancer. 
4.4 PAPER IV 
Prognostic potential of automated Ki67 evaluation in breast cancer: different hot spot 
definitions versus true global score 
As concluded in paper III, hot spot Ki67 scoring by DIA virtual double staining is the 
suggested marker of choice for assessment of proliferation in primary breast cancer. In Sweden, 
Ki67 counting in the hottest area of the tumour containing 200 cells, a so-called hot spot has 
been adopted for manual scoring, whereas other countries recommend counting an average 
Ki67 score across the entire tumour. With the rapid development of DIA systems, average 
scoring of >1000 cells can efficiently be performed.  
Based on the results from paper III, we first sought to further investigate the prognostic 
influence of different parameters defining the hot spot for DIA evaluation of Ki67. The Clinseq 
cohort of 139 ER-positive/HER2-negative primary breast tumours with digitised whole-slide 
images of Ki67 and CKMNF116 was used for DIA scoring of Ki67. Across 19 different 
algorithms (apps) for hot spot scoring, those with higher scored number of cells had greater 
reproducibility in terms of intraclass correlation coefficients. Among the configurable hot spot 
apps, APP24 had the highest risk for recurrence in high versus low Ki67 cases and was selected 
for further comparisons. This app included 400 cells, 40x field of view and a heatmap-shaped 
hot spot. Regarding risk for overall death, a similar app including 1200 cells had slightly higher 
HR than APP24.  
The prognostic value of the selected hot spot app was thereafter compared against true global 
(average) Ki67 scoring using a different DIA platform (QuPath). The global scoring had lower 
median Ki67 values than all hot spot apps, which has been reported previously184. Hot spot 
APP24 had twice as high HR for recurrence as global scoring among high versus low Ki67 
cases. Regarding risk for overall death, global scoring was however superior, which was also 
seen among node-negative cases.  
We further investigated the prognostic significance in adjusted multivariate Cox regression 
models estimating the HR associated with RFS or OS among high versus low Ki67 cases. 
Importantly, we found that only global Ki67 scoring added independent prognostic information 
to the model associated to both RFS and OS. 
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Molecular subtypes based on PAM50 algorithm showed that luminal B cases had an increased 
risk associated with both RFS and OS as opposed to luminal A cases. This is in line with the 
established data on the prognostic value of molecular subtypes as discussed in section 1.7. We 
then applied IHC-based surrogate subtype classifications to distinguish luminal A-like from 
luminal B-like based on Ki67 values from each method. The global scoring provided higher 
concordance with PAM50 subtype than hot spot scoring. Further, the global method also 
showed increased HR for OS in luminal B-like versus luminal A-like cases. 
In summary, we showed similar outcome prediction using DIA hot spot in VIS and global Ki67 
scoring in QuPath, but only the global method had independent prognostic value associated to 
both RFS and OS. In addition, the global method is a more practical method that could be 
adopted in a digital work flow for automated Ki67 assessment in breast pathology. Prior to 
clinical implementation, these findings need to be confirmed in a larger independent cohort. 
4.5 PAPER V 
Detailed investigation and re-assessment of HER2 status in breast cancer patients 
treated with HER2-targeted therapy 
Advances in HER2-targeted therapy, pioneered by trastuzumab, have dramatically improved 
survival for patients with HER2-positive breast cancer. Unfortunately, some patients progress 
despite HER2-targeted therapy. Assessment of HER2 status by IHC and ISH has been the 
standard method since the introduction of trastuzumab, but is however, insufficient to identify 
patients with therapy-resistant disease.  
In a retrospective cohort of 591 patients with HER2-positive breast cancer treated with 
trastuzumab, we investigated the prognostic value of HER2 status on the protein, DNA and 
targeted mRNA level. By performing HER2 ISH re-testing on 460 tumours, we examined the 
association of HER2 copy numbers and HER2/CEP17 ratio with RFS and BCSS. Measurement 
of ERBB2 transcript mRNA levels was performed with the STRAT4 assay.  
Neither HER2 copy numbers (³6.0 vs <6.0), HER2/CEP17 ratio (³2.0 vs <2.0) nor ER status 
provided any prognostic value in terms of RFS or BCSS. Higher HER2 copy numbers and ratio 
was identified among HER2-positive/ER-negative tumours compared to ER-positive, but no 
difference in prognosis was observed.  
Results from the STRAT4 assay revealed that 85% had transcript mRNA levels scored as 
ERBB2 ‘positive’ and 15% did not reach the pre-defined cut-off, thus scored ERBB2 
‘negative’. However, among the ERBB2 ‘negative’ tumours almost 50% were HER2 protein 
overexpressing (IHC 3+) and gene amplified by ISH. Interestingly, survival analysis and Cox 
regression analysis showed that ERBB2 ‘negative’ tumours were associated with disease 
recurrence, and ERBB2 remained an independent prognostic factor in multivariate analysis 
adjusted for lymph node status. Approximately 20% of the ER-positive tumours were ERBB2 
‘negative’. For ER-positive tumours, ‘negative’ ERBB2 levels were significantly associated 
with risk of recurrence. 
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Furthermore, when we analysed patients presenting with recurrent disease (12%), there was no 
significant difference in HER2 copy numbers or ratio compared to those without recurrence.  
However, when divided by ER status, ER-negative tumours had significantly higher HER2 
copy numbers, ratio and ERBB2 levels. 
In summary, our findings showed that routine clinicopathological information is insufficient to 
discriminate those patients who are or will become HER2-resistant and progress despite 
trastuzumab treatment. We demonstrate that neither HER2 copy numbers nor HER2/CEP17 
ratio or ER status, but low levels of ERBB2 mRNA, which may more accurately indicate the 
HER2 protein levels, were associated with risk of recurrence. 
 
4.6 CONCLUSIONS  
The findings presented in paper I-V within this thesis can be summarised as follows:  
• Discordances in biomarker status from aspiration cytology and paired surgical 
resections from breast tumours, and the limited prognostic potential of ICC-based Ki67 
scoring demonstrates that IHC is the superior method for Ki67 evaluation.  
• Discordances in Ki67 and HER2 status between CNB and paired resection 
demonstrates that these biomarkers should be re-tested on all surgical breast cancer 
specimens. 
• Digital image analysis using virtual double staining in VIS of hot spot Ki67 
outperforms alternative markers of proliferation in breast cancer. 
• Automated global scoring of Ki67 in QuPath has independent prognostic potential 
compared to hot spots in VIS, and is a practical method for routine Ki67 scoring in 
breast pathology. 
• Low levels of ERBB2 mRNA, but neither HER2 copy numbers, HER2 ratio nor ER 
status, are associated with risk of recurrence among anti-HER2 treated breast cancer 
patients. 
 
 
4.7 GENERAL DISCUSSION 
The accuracy of prognostic and predictive biomarker assessment in breast tumours is crucial 
for management and therapy decision in patients with breast cancer. In the papers presented 
within this thesis, biomarkers used in clinical practice with emphasise on Ki67 and HER2 were 
studied using several methods. These studies cover methods including ICC and IHC, ISH, gene 
expression assays and DIA, with the overall aim to improve routine biomarker evaluation and 
clarify the prognostic potential. 
ER, PR, HER2 and Ki67 are routinely evaluated for all invasive breast tumours and hold 
therapy-predictive and prognostic information that can be combined to represent molecular 
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subtypes (see section 1.8 for details). Multigene signature assays for risk stratification are 
available for selected patient groups but are not implemented in the routine management of 
breast cancer in Sweden due to high costs. Therefore, since IHC-based biomarker evaluations 
are used for clinical surrogate subtype classification, biomarker scores need to be accurate. 
Among patients with luminal A- and luminal B-like tumours, Ki67 together with grade and PR 
help distinguish the high-proliferative luminal B-like tumours with benefit from added 
chemotherapy from the low-proliferative luminal A-like tumours with good prognosis on only 
endocrine therapy. 
The discordance between Ki67 scoring from FNAC and corresponding surgical specimens 
presented in paper I could partly be explained by tumour heterogeneity and tumour material 
representing different areas of the tumour, as well as the two different methods used. By using 
fine-needle aspiration-derived cell blocks for IHC, HER2 testing on cytological material is 
possible, and is also suggested to improve biomarker concordance406, 407. Ki67 was scored in a 
selected hot spot area on whole-slide sections from surgical specimens, whereas ICC-based 
scoring from FNAC represents non-specific small portions of the tumour. As opposed to ER, 
both Ki67 and PR are more heterogeneously expressed across the tumour136, 408. From our 
findings in paper I, it was concluded that ICC-scored Ki67 from aspiration cytology cannot be 
regarded as a reliable prognostic measure for overall survival outcome. However, FNAC-based 
ICC of Ki67 was previously demonstrated to be a prognosticator of disease recurrence-free 
interval409. We also showed that both surrogate subtype classification (St Gallen 2013) based 
on ICC and IHC had limited agreement with molecular subtype, which regarding ICH is in line 
with previous concordance rates255. Despite the lack of prognostic value of Ki67 from cytology 
in our study, FNAC is still a valuable method for diagnosing malignancy. We compared 
cytology with re-evaluated Ki67 and ER scores in surgical specimens of primary tumours; 
however, in the metastatic setting FNAC may be the only method of choice for diagnosis and 
biomarker assessment. Our findings in primary tumours suggest that ER scoring is reliable on 
cytological material but Ki67 has limited value, which might reflect on the metastatic setting. 
HER2 status was generally not assessed from cytology in our study data, which however, along 
with ER is the clinically most important biomarker for patients with metastatic disease. When 
a tumour already has progressed to a metastatic state, tumour proliferation may add limited 
information for therapy decisions. 
Ki67 along with HER2 status discordance between CNB and surgical specimens when 
evaluating the same tumours were demonstrated in paper II. Although a 3.6% discordance rate 
for HER2 status is seemingly low, for the individual patient approximately 1 in 25 could 
potentially receive the wrong therapy, leading to serious implications for patients not receiving 
HER2-targeted therapies. The use of NAC has increased, and up to 17% of patients with early 
breast cancer were treated with neoadjuvant therapy in Sweden during 201913. Neoadjuvant 
treatment provides an opportunity to histologically evaluate the effect of given therapies, and 
to plan adjuvant therapies accordingly. From our findings in paper II, we reported on the 
importance to re-test biomarkers on all surgical specimens. The observed discordances could 
mainly be due to the intratumoural heterogeneity of biomarker expression and the difference 
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in tumour representation in a CNB compared with surgical excisions. The 2013 ASCO/CAP 
guidelines for HER2 testing state that tumours with initially negative HER2 status on CNBs 
must be re-tested on the specimen73. However, the latest 2018 ASCO/CAP guidelines do not 
require re-testing of HER2 on surgical specimens with initially negative status; only in cases 
of NHG 3 and equivocal HER2 results a new test may be performed162. Furthermore, it is still 
debatable whether resistance to chemotherapy is caused by selection of clones or through 
acquisition of new genomic alterations. Single-cell sequencing of triple-negative breast 
tumours prior to, during and after NAC illustrated both the presence of pre-existing genomic 
alterations and induced transcriptional reprogramming of chemo-resistant signatures410.  
In paper III, the Visiopharm VIS double staining method was applied for investigating the 
optimal region of Ki67 scoring, and cut-offs for each method were adjusted by AUC-ROC for 
OS and RFS (all cause-mortality). This rendered a cut-off at 36% for hot spots, 17% for 
invasive edges and 12% for full sections. Thus, different cut-offs for each method were used 
in the Cox regression analysis. Further, AUC-ROC for discriminating luminal B versus luminal 
A yielded a cut-off at 26% for hot spots, 23.5% for invasive edges and 13.5% for full section. 
The intention of this study was to find the optimal scoring for proliferative activity by 
comparing several markers both by manual and digital virtual double staining algorithms. The 
digital full section scoring was performed by the software sampling 25% of the tumour area, 
as opposed to counting all cells (for global scoring in paper IV). The finding that DIA scoring 
of Ki67 using the virtual double staining-based hot spot app was the superior method, led to 
the attempt to try and define an optimal hot spot in paper IV. The Ki67 hot spot app in VIS 
provided the opportunity to investigate the prognostic value of different configurable 
parameters such as cell counts, shape and how the algorithm detected the hot spot. However, 
the virtual double staining method is not an efficient method for routine use in breast pathology 
since it requires an additional parallel cytokeratin-stained section. The emerging evidence for 
average (global) Ki67 scoring by DIA, especially in terms of reproducibility182, suggested to 
compare our best hot spot app with an automated global scoring using QuPath. Since the 
QuPath algorithm was trained to score Ki67 based on Ki67 IHC sections alone, its clinical 
application is more feasible. In this setting, we used a cut-off at 20% for both methods. As our 
results showed, global scoring in QuPath showed independent prognostic potential. However, 
before clinical implementations of a global scoring method, our findings need to be validated 
in a separate cohort. The current cut-offs in Sweden apply for manual hot spot scoring, and 
adjusted cut-offs for automated global scoring need to be investigated. 
The controversies around Ki67 mainly concern the reproducibility of the biomarker. Apart 
from scoring methodology, e.g. hot spot versus global or manual versus automated scoring, 
which was investigated extensively in paper III and IV, there are several other factors that 
influence Ki67 assessments. Fixation times, antibody clone, antigen retrieval heating times and 
staining techniques are all parameters that may affect Ki67 evaluation108. In a Swedish cohort 
there was no difference in reproducibility or prognostic value between the rabbit monoclonal 
antibody SP6 and the mouse monoclonal antibody MIB1411. For image analysis, SP6 is 
substantially better suited than MIB1, due to reduced background412. In addition, Focke et al. 
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showed that the interlaboratory variability of Ki67 and luminal A-like classifications remains 
even when the same antibody clones (30-9, MIB1 and SP6) are used413. It is therefore important 
that each pathology department has standardised protocols and internal monitoring of Ki67. In 
addition, external monitoring increases quality assurance. In the papers of this thesis, rabbit 
anti-Ki67 monoclonal antibody clone 30-9 (Ventana Medical Systems) was used repeatedly. 
The alternative marker for proliferation that we studied in paper IV, PHH3, did not prove to 
provide significant prognostic value. Worth mentioning is that prior to routine use of Ki67, 
several other markers of proliferative activity have been used in different Swedish pathology 
departments, such as DNA flow cytometry determination of S phase414 and cell cycle regulating 
cyclins112. 
Histological grade has unquestionable clinical value88, 89, but there is a variability in scoring. 
Preliminary results from an ongoing study revealed variability in biomarker status across 
Swedish pathology departments, especially for grade and Ki67, despite using the same 
guidelines as well as and internal and external quality assurance programmes (abstract from 
SABCS 2019)415. Histological grading can be improved with DIA by combining DIA-scored 
Ki67 as shown in paper III. Instead of the subjective measure of mitoses and nuclear 
pleomorphism, grading by computerised methods provides clear reproducibility and thus more 
robust histological grade. Since NHG 2 tumours provide limited clinical information, efforts 
have also been made to dichotomise these into low and high transcriptomic grade based on 
gene- and isoform-level expression data from RNA sequencing393. Furthermore, trained AI 
models are promising for dichotomising NHG 2 tumours into either good or bad prognostic 
groups, resembling a two-tier grading system (Wang et al., unpublished).  
With the complexity and heterogeneity of breast cancer, the prognostic and predictive 
information in each biomarker can no longer be analysed separately but needs to be considered 
together with grade, lymph node status and molecular subtypes. Based on the findings in paper 
IV, it would be of interest to include grade and the proposed three-tier classification of Ki67 
(low-intermediate-high) by Maisonneuve et al.254, which is also adopted by the Swedish 
recommendations, in future validation studies of computer-aided scoring. Determining a single 
cut-off value for dichotomising tumours into luminal A-like and luminal B-like has not proven 
to be clinically applicable. The clearly low proliferative or highly proliferative tumours are not 
the cause of the controversies, since clinical decisions regarding therapeutic choices for these 
groups are well studied. Instead, the challenge concerns the intermediate Ki67 values around 
15-25%, and identifying those patients who would actually benefit from added chemotherapy 
from those who instead would risk suffering from cytotoxic side effects with no added survival 
benefit.   
Although HER2 is an established predictive biomarker for the benefit of HER2-targeted 
therapy, it is insufficient to predict disease recurrence. In paper V we demonstrate HER2 
investigations on a DNA, RNA and protein level; additional RNA level data e.g. on molecular 
subtypes would be of interest to distinguish the luminal HER2-positive tumours from the true 
HER2-enriched tumours. As we could show, routine HER2 IHC and ISH status was not 
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associated with risk of recurrence. On the contrary, we found low ERBB2 levels associated 
with increased recurrence risk. The correlation of STRAT4 ERBB2 levels, especially those 
cases with low ERBB2, and HER2-enriched subtypes would be interesting to investigate in 
this HER2-positive cohort. In addition, differences in intensities of HER2 IHC 2+ among 
ERBB2 ‘negative’ and ‘positive’ tumours would be valuable to see if the mRNA levels can be 
well reflected by IHC. In paper V, pre-set cut-offs404 were used to discriminate ERBB2 
‘positive’ versus ‘negative’ tumours. Since other antibodies as well as fluorescent ISH, were 
used to set these pre-defined cut-offs and without outcome correlation, it would be important 
to investigate prognostic cut-points for risk of recurrence in our HER2-positive trastuzumab-
treated cohort. HER2 mRNA measurements as a continuous value may better reflect the HER2 
status than IHC/ISH. Apart from this, especially in resource-limited settings, a quick closed-
system targeted gene expression assay for routine biomarkers, has potential to provide 
diagnostic information that may otherwise not be available. 
The tumour microenvironment and stromal factors have proven to play an important role in 
breast cancer progression. In HER2-positive breast cancer, the presence of TILs is correlated 
to improved outcomes in the neoadjuvant setting416. Apart from studying HER2 expression and 
gene amplification, we speculate that assessment of TILs in our adjuvant trastuzumab-treated 
HER2-positive cohort may provide important prognostic information. The results from paper 
V also highlight the need for more detailed molecular analyses to further understand the biology 
behind resistance to HER2-targeted therapy. Thus, we speculate that a future molecular model 
would incorporate image analysis of protein expression staining intensities and heterogeneity, 
molecular subtypes and PI3K pathway status in order to predict sensitivity to targeted therapies. 
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5 FUTURE PERSPECTIVES 
The field of surgical pathology and breast pathology specifically is rapidly evolving with 
digitised work flows and molecular techniques, moving towards comprehensive precision 
pathology. With all emerging targeted therapies and companion diagnostics that follows, the 
pathological evaluation will need to be continuously updated for accurate assessment. Some 
future perspectives for improving biomarker evaluation are presented in the following sections.  
5.1 CELL-BASED METHODS 
Cytology is a minimally invasive method that provides unique possibilities to retrieve tumour 
material from organ sites not available for biopsy sampling, e.g. distant visceral metastases. 
Advances in image analysis have shown promising results also for cytology and AI algorithms 
may further improve accuracy. In addition, cytological tumour material derived from fine-
needle aspirations are also perfect for NGS and a valuable source for molecular analysis of 
metastatic lesions417.  
Liquid biopsies, either circulating tumour cells or circulating tumour DNA is a rapidly 
emerging field in precision oncology. Still there are uncertainties regarding clinical validity 
and clinical utility, especially in early-stage disease76, 418. Tumour cells in liquid biopsies may 
potentially act as surrogates for the tissue-based tumour and provides an opportunity to monitor 
tumour biological changes419. Molecular characterisation and biomarker status (e.g. ER, HER2, 
Ki67) can be measured in circulating tumour cells420, 421, but whether or not these predict 
clinical response or outcome remains uncertain46. For example, HER2 positivity was not 
predictive of response to lapatinib422. 
5.2 TUMOUR HETEROGENEITY AND BIOMARKER CONCORDANCE 
The tumour heterogeneity is a complicating factor in clinical practice and cancer treatment, 
since tumour samples may not represent the entire tumour and therefore the evaluation may 
vary both between sampling methods and areas within the tumour41. Rye et al. recently 
demonstrated on a single-cell level that intratumoural heterogeneity for HER2 copy number 
was associated with worse outcome48. Sampling from several areas of the tumour may provide 
insights into spatial heterogeneity. 
As demonstrated in several of the papers in this thesis, there were discordances between IHC-
based subtypes and PAM50 intrinsic subtypes, which has also been reported by others226, 255. 
Since molecular subtyping covers a large number of genes that together cluster and define the 
intrinsic subtype, one cannot assume that IHC-based subtyping of only ER, PR, HER2 and 
Ki67 would provide the same classification; it is therefore important to acknowledge that IHC-
based subtypes act as surrogates. However, there is rather limited research to increase the 
consistency of PAM50- and IHC-based subtypes. The clinically approved molecular signatures 
assays will most likely become part of routine pathology for assigning not only molecular 
subtype but also for risk stratification.  
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5.3  OVERCOMING KI67 CONTROVERSIES 
With over a decade of controversies regarding Ki67 scoring, we will probably leave hot spot 
methods and see a general acceptance of computerised global counting of Ki67. Since current 
cut-offs for Ki67 scoring in Sweden is based on hot spots, new cut-offs need to be investigated 
in larger cohorts prior to implementation. Clearly high and low proliferation by Ki67 provides 
prognostic value but for the intermediate group additional methods are required. Over the last 
few years, the use of gene expression signature assays has been more widely adopted for 
clinical practice. In the latest Swedish national guidelines, gene expression assays are 
recommended for patients with ER-positive/HER2-negative NHG 2 tumours with intermediate 
Ki67 in order to distinguish luminal A from luminal B subtypes in those patients were therapy 
decisions could be affected by subtype classification. Furthermore, IHC of Ki67 could 
altogether be replaced by a whole group of proliferation genes on mRNA level from e.g. 
PAM50 assays.  
5.4 FUTURE HER2 TESTING  
Evaluation of HER2 ISH is both time-consuming and to some extent hampered by 
reproducibility issues. Automated machine learning approaches are under development for 
HER2 ISH scoring by e.g. Roche and will most certainly provide improved reproducibility and 
more efficient assessment. DIA methods such as QuPath could provide opportunities to further 
investigate the association of IHC 2+ staining intensities and the level of mRNA expression in 
our trastuzumab treated HER2-positive cohort. In addition to tissue-based assessment, HER2 
status can be detected in liquid biopsies both using serum (HER2 levels) and in circulating 
tumour cells420. 
Genomic profiling of solid tumours including breast cancer is becoming a part of precision 
medicine. In the United States, FoundationOne CDx by Roche Foundation Medicine was the 
first FDA approved companion diagnostic for genomic profiling. In Sweden, FoundationOne 
CDx is available on request for selected patients. Genomic profiling provides opportunities to 
investigate and analyse gene copy numbers by DNA sequencing and mutations in the HER2 
gene.  
One can speculate that not only ERBB2/HER2 mRNA levels but also levels of the ESR1, PGR 
and MKi67 are important to discriminate therapy responsive patients. Based on gene 
expression analysis, further studies are ongoing to subgroup patients into intrinsic molecular 
subtypes and HER2 expression may have different prognostic value in different subtypes. 
Hence, the aim is to proceed with an anti-HER2 response prediction algorithm based on all 
four quantitative biomarkers within the trastuzumab-treated HER2-positive cohort. Regarding 
sequencing of HER2, there are two possibilities: either to analyse HER2 copies by RNA 
sequencing or to count gene copies on DNA level by DNA sequencing. However, RT-qPCR 
assays for measuring mRNA levels, which is an accessible and rapid method not relying on 
specialised pathologists may have large potential for improved biomarker assessment in 
resource-limited settings. 
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5.5 NOVEL BIOMARKERS AND COMPANION DIAGNOSTICS 
Apart from the four routine biomarkers, ER, PR, HER2 and Ki67, in breast pathology that have 
been investigated in the work of this thesis, several novel biomarkers and companion 
diagnostics are entering the diagnostic spectrum of breast pathology. As mentioned, the 
tumour-immune cell interaction plays an evident role in tumour progression423-425. TILs predict 
clinical outcome in breast cancer426-428 and are currently included in the diagnostic evaluation 
of triple-negative breast cancer72, 194. Scoring of TILs has demonstrated to be a predictor of 
complete response to chemotherapy in patients with HER2-positive disease and associated with 
benefit of trastuzumab but further evidence of the clinical relevance in the adjuvant setting is 
needed192, 427-429. TILs scoring from HE may potentially be a simple method for identifying 
patients with excellent prognosis and play a role in guiding therapy de-escalation and for 
designing clinical trials. 
Despite targeted therapies, the development of therapy resistance is a complicating factor in 
breast cancer management. Gene expression analysis could be used to potentially detect altered 
expression in key pathways, e.g. PI3K or MAPK overexpression that could indicate therapy 
resistance as discussed in section 1.11. 
5.6 AI APPROCHES FOR PRECISION PATHOLOGY 
During the last decade we have seen ground-breaking advances in AI and computerised 
pathology, which today also includes aspects of precision pathology.  
AI models can be trained to detect and grade prostate cancer with expert-level performance430, 
and similar AI approaches are ongoing for grading of breast cancer. Breast tumours of NHG 2, 
e.g., provide limited clinical information, and trained AI models can dichotomised these into 
either good or bad prognostic groups, resembling a two-tier grading system (Wang et al, 
manuscript). Apart from aiding the diagnostic process and fairly simple tasks such as biomarker 
scoring, AI models hold promise to capture prognostic and predictive information from HE-
stained tumour images, which the human eye cannot interpret through the bright field 
microscope. Instead of using IHC stained images for Ki67 scoring, we speculate that deep 
learning models could be applied to predict proliferational activity directly from HE. In the 
recent work by Kather et al., deep learning models could detect high-proliferation versus low-
proliferation signatures in lung and gastric cancer431. The demand for molecular profiling of 
tumours for selecting patients eligible for targeted or biomarker-based therapies is increasing. 
However, the turnaround time and costs for these assays are considerable, and applying AI 
models for this task is an efficient yet challenging alternative. Deep learning-based AI models 
have shown promising abilities to detect gene mutations in lung cancer432, prostate cancer433 
and uveal melanoma434, as well as predict molecular subtypes in breast cancer435. Furthermore, 
spatial transcriptomics and histological features can be combined to predict gene expression in 
breast cancer436. Two recent studies demonstrated that deep learning can predict genomic 
alterations based on morphological features from HE images across several cancer types431, 437. 
Apart from detecting molecular subtypes, the models could predict mutation status of several 
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genes across different cancer types, including MAP3K1, TP53, PIK3CA, FOXA1 and MAP2K4 
in breast cancer. In addition, pan-cancer models showed better prediction of prognosis than 
using grade and subtype437. In summary, AI-based methods for image analysis will not only 
transform the way pathologists diagnose cancer but also change the way how clinicians 
interpret diagnostic data. Most likely, in the next few years, we will see the first AI methods 
get introduces into routine pathology. 
To summarise, the complexity of tumour biology and emerging combinations of targeted 
therapies pose diagnostic challenges. Future diagnostic methods for therapy-prediction and 
prognostication might involve advanced deep learning algorithms combining morphology, 
grade and perhaps IHC-stained biomarkers to select patients for whom additional sequencing 
of the tumour would actually be beneficial.  
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